<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE Publisher PUBLIC "-//Springer-Verlag//DTD A++ V2.4//EN" "http://devel.springer.de/A++/V2.4/DTD/A++V2.4.dtd">
<Publisher>
  <PublisherInfo>
    <PublisherName>Springer New York</PublisherName>
    <PublisherLocation>New York, NY</PublisherLocation>
    <PublisherImprintName>Springer</PublisherImprintName>
  </PublisherInfo>
  <Book Language="En">
    <BookInfo BookProductType="Contributed volume" ContainsESM="No" Language="En" MediaType="eBook" NumberingStyle="ChapterOnly" OutputMedium="All" TocLevels="0">
      <BookID>978-1-60327-829-4</BookID>
      <BookTitle>Drug Management of Prostate Cancer</BookTitle>
      <BookDOI>10.1007/978-1-60327-829-4</BookDOI>
      <BookTitleID>158057</BookTitleID>
      <BookPrintISBN>978-1-60327-831-7</BookPrintISBN>
      <BookElectronicISBN>978-1-60327-829-4</BookElectronicISBN>
      <BookChapterCount>37</BookChapterCount>
      <BookCopyright>
        <CopyrightHolderName>Springer Science+Business Media, LLC</CopyrightHolderName>
        <CopyrightYear>2010</CopyrightYear>
      </BookCopyright>
      <BookSubjectGroup>
        <BookSubject Code="SCH" Type="Primary">Medicine &amp; Public Health</BookSubject>
        <BookSubject Code="SCH33160" Priority="1" Type="Secondary">Oncology</BookSubject>
        <BookSubject Code="SCH62002" Priority="2" Type="Secondary">Urology</BookSubject>
        <BookSubject Code="SCH33002" Priority="3" Type="Secondary">Internal Medicine</BookSubject>
        <SubjectCollection Code="SUCO11650">Medicine</SubjectCollection>
      </BookSubjectGroup>
    </BookInfo>
    <BookHeader>
      <EditorGroup>
        <Editor AffiliationIDS="AffID1">
          <EditorName DisplayOrder="Western">
            <GivenName>William D.</GivenName>
            <FamilyName>Figg</FamilyName>
          </EditorName>
          <Contact>
            <Phone>301402-3622</Phone>
            <Fax>301402-8606</Fax>
            <Email>wdfigg@helix.nih.gov</Email>
          </Contact>
        </Editor>
        <Editor AffiliationIDS="AffID2">
          <EditorName DisplayOrder="Western">
            <GivenName>Cindy H.</GivenName>
            <FamilyName>Chau</FamilyName>
          </EditorName>
          <Contact>
            <Email>chauc@mail.nih.gov</Email>
          </Contact>
        </Editor>
        <Editor AffiliationIDS="AffID3">
          <EditorName DisplayOrder="Western">
            <GivenName>Eric J.</GivenName>
            <FamilyName>Small</FamilyName>
          </EditorName>
          <Contact>
            <Phone>415/353-7171</Phone>
            <Email>smalle@medicine.ucsf.edu</Email>
          </Contact>
        </Editor>
        <Affiliation ID="AffID1">
          <OrgDivision>Medical Oncology Branch</OrgDivision>
          <OrgName>NIH National Cancer Institute</OrgName>
          <OrgAddress>
            <Street>Rockville Pike 9000</Street>
            <City>Bethesda</City>
            <Postcode>20892</Postcode>
            <State>Maryland</State>
            <Country>USA</Country>
          </OrgAddress>
        </Affiliation>
        <Affiliation ID="AffID2">
          <OrgDivision>Medical Oncology Branch</OrgDivision>
          <OrgName>NIH National Cancer Institute</OrgName>
          <OrgAddress>
            <Street>Rockville Pike 9000</Street>
            <City>Bethesda</City>
            <Postcode>20892</Postcode>
            <State>Maryland</State>
            <Country>USA</Country>
          </OrgAddress>
        </Affiliation>
        <Affiliation ID="AffID3">
          <OrgDivision>School of Medicine, Dept. Urology</OrgDivision>
          <OrgName>University of California, San Francisco</OrgName>
          <OrgAddress>
            <Street>Divisadero Street 1600</Street>
            <City>San Francisco</City>
            <Postcode>94115</Postcode>
            <State>California</State>
            <Country>USA</Country>
          </OrgAddress>
        </Affiliation>
      </EditorGroup>
    </BookHeader>
    <Part ID="Part2">
      <PartInfo OutputMedium="All" TocLevels="0">
        <PartID>2</PartID>
        <PartNumber>Part I</PartNumber>
        <PartSequenceNumber>2</PartSequenceNumber>
        <PartTitle>Hormone Therapy</PartTitle>
        <PartChapterCount>9</PartChapterCount>
        <PartContext>
          <BookID>978-1-60327-829-4</BookID>
          <BookTitle>Drug Management of Prostate Cancer</BookTitle>
        </PartContext>
      </PartInfo>
      <Chapter ID="Chap2" Language="En">
        <ChapterInfo ChapterType="OriginalPaper" ContainsESM="No" Language="En" NumberingStyle="ChapterOnly" OutputMedium="All" TocLevels="0">
          <ChapterID>2</ChapterID>
          <ChapterNumber>Chapter 2</ChapterNumber>
          <ChapterDOI>10.1007/978-1-60327-829-4_2</ChapterDOI>
          <ChapterSequenceNumber>2</ChapterSequenceNumber>
          <ChapterTitle Language="En">Luteinizing Hormone-Releasing Hormone and Its Agonistic, Antagonistic, and Targeted Cytotoxic Analogs in Prostate Cancer</ChapterTitle>
          <ChapterFirstPage>27</ChapterFirstPage>
          <ChapterLastPage>39</ChapterLastPage>
          <ChapterCopyright>
            <CopyrightHolderName>Springer Science+Business Media, LLC</CopyrightHolderName>
            <CopyrightYear>2010</CopyrightYear>
          </ChapterCopyright>
          <ChapterHistory>
            <RegistrationDate>
              <Year>2010</Year>
              <Month>4</Month>
              <Day>16</Day>
            </RegistrationDate>
            <OnlineDate>
              <Year>2010</Year>
              <Month>8</Month>
              <Day>3</Day>
            </OnlineDate>
          </ChapterHistory>
          <ChapterGrants Type="Regular">
            <MetadataGrant Grant="OpenAccess"/>
            <AbstractGrant Grant="OpenAccess"/>
            <BodyPDFGrant Grant="Restricted"/>
            <BodyHTMLGrant Grant="Restricted"/>
            <BibliographyGrant Grant="Restricted"/>
            <ESMGrant Grant="Restricted"/>
          </ChapterGrants>
          <ChapterContext>
            <PartID>2</PartID>
            <BookID>978-1-60327-829-4</BookID>
            <BookTitle>Drug Management of Prostate Cancer</BookTitle>
          </ChapterContext>
        </ChapterInfo>
        <ChapterHeader>
          <AuthorGroup>
            <Author AffiliationIDS="Aff1_2 Aff2_2" CorrespondingAffiliationID="Aff1_2">
              <AuthorName DisplayOrder="Western">
                <GivenName>Andrew</GivenName>
                <GivenName>V.</GivenName>
                <FamilyName>Schally</FamilyName>
              </AuthorName>
              <Contact>
                <Email>andrew.schally@va.gov</Email>
              </Contact>
            </Author>
            <Author>
              <AuthorName DisplayOrder="Western">
                <GivenName>Norman</GivenName>
                <GivenName>L.</GivenName>
                <FamilyName>Block</FamilyName>
              </AuthorName>
            </Author>
            <Affiliation ID="Aff1_2">
              <OrgDivision>Department of Veterans Affairs, VA Research Services</OrgDivision>
              <OrgName>Veterans Affairs Medical Center</OrgName>
              <OrgAddress>
                <City>Miami</City>
                <State>FL</State>
                <Country>USA</Country>
              </OrgAddress>
            </Affiliation>
            <Affiliation ID="Aff2_2">
              <OrgDivision>Division of Hematology/Oncology and Division of Endocrinology, Departments of Pathology and Medicine, Miller School of Medicine</OrgDivision>
              <OrgName>University of Miami</OrgName>
              <OrgAddress>
                <City>Miami</City>
                <State>FL</State>
                <Country>USA</Country>
              </OrgAddress>
            </Affiliation>
          </AuthorGroup>
          <Abstract ID="Abs1_2" Language="En" OutputMedium="All">
            <Heading>Abstract</Heading>
            <Para TextBreak="No">Chronic administration of luteinizing hormone-releasing hormone I (LHRH-I) or its agonistic analogs leads to downregulation of pituitary receptors for LHRH, and a gradual suppression of circulating levels of gonadotropins and sex steroids. The creation of a state of sex-hormone deprivation produced by periodic administration of sustained delivery system of LHRH agonists forms the basis of therapy for advanced prostate cancer and other malignant neoplasms. LHRH antagonists developed in recent decades bind competitively to LHRH receptors and cause an immediate inhibition of the release of gonadotropins and sex steroids. This rapid induction of sex-hormone deprivation by LHRH antagonists makes them useful for the treatment of prostate cancer and other sex steroid-dependent cancers. Potent LHRH-I antagonists are finding important clinical applications in urology, oncology, and gynecology. In addition to their suppressive effects on sex-hormone secretion induced by the downregulation of pituitary LHRH receptors, LHRH agonists and antagonists also exert direct inhibitory actions on tumors, which are mediated by tumoral LHRH receptors. These direct actions contribute to the therapeutic effects of LHRH analogs on cancers and in the case LHRH-I antagonists are also utilized for the treatment of benign prostatic hyperplasia (BPH). In this chapter, we review some selected endocrine and antitumoral effects of LHRH agonists and antagonists and clinical trials on prostate cancer and BPH. Experimental studies and early clinical trials with targeted cytotoxic LHRH analogs developed recently for targeted chemotherapy of tumors expressing LHRH receptors are also described.</Para>
          </Abstract>
          <KeywordGroup Language="En" OutputMedium="All">
            <Heading>Keywords</Heading>
            <Keyword>LH secretion</Keyword>
            <Keyword>FSH secretion</Keyword>
            <Keyword>Sex steroid</Keyword>
            <Keyword>Gonadotropin</Keyword>
            <Keyword>Chemical castration</Keyword>
            <Keyword>Anticancer effects</Keyword>
            <Keyword>Tumor growth</Keyword>
            <Keyword>Cell proliferation</Keyword>
            <Keyword>LHRH-receptor</Keyword>
          </KeywordGroup>
        </ChapterHeader>
        <Body>
          <Section1 ID="Sec1" Type="Introduction">
            <Heading>Introduction</Heading>
            <Para TextBreak="No">Luteinizing hormone-releasing hormone I (LHRH-I) also called gonadotropin-releasing hormone (GnRH) plays a key role in the regulation of reproduction by controlling the secretion of luteinizing hormone (LH) and follicle stimulating hormone (FSH) from the anterior pituitary gland [<CitationRef CitationID="CR1_2">1</CitationRef>, <CitationRef CitationID="CR2_2">2</CitationRef>]. Thus, LHRH regulates gametogenesis and sex steroid hormone secretion from the gonads [<CitationRef CitationID="CR1_2">1</CitationRef>–<CitationRef CitationID="CR7_2">7</CitationRef>].</Para>
            <Para TextBreak="No">The isolation, determination of structure (Fig. <InternalRef RefID="Fig1">2.1</InternalRef>), and synthesis of decapeptide (LHRH I) in the laboratory of one of us (AVS) in 1971 has had a major impact on endocrinology, gynecology, and oncology [<CitationRef CitationID="CR1_2">1</CitationRef>, <CitationRef CitationID="CR2_2">2</CitationRef>, <CitationRef CitationID="CR6_2">6</CitationRef>, <CitationRef CitationID="CR7_2">7</CitationRef>]. Various agonistic analogs of LHRH were rapidly developed in view of their expected medical applications [<CitationRef CitationID="CR2_2">2</CitationRef>, <CitationRef CitationID="CR6_2">6</CitationRef>, <CitationRef CitationID="CR7_2">7</CitationRef>]. The effects of LHRH are mediated by high-affinity G protein-coupled receptors found on pituitary gonadotrophs and various extrapituitary sites [<CitationRef CitationID="CR3_2">3</CitationRef>–<CitationRef CitationID="CR5_2">5</CitationRef>]. Responses to LHRH vary under different conditions and depend on administration and doses delivered to the gonadotroph cells. Continuous administration of LHRH or its potent agonistic analogs, such as Decapeptyl, Leuprolide, Goserelin, and Buserelin, leads to downregulation of pituitary receptors for LHRH and suppression of circulating levels of LH, FSH, and sex steroids [<CitationRef CitationID="CR5_2">5</CitationRef>–<CitationRef CitationID="CR7_2">7</CitationRef>]. Treatment of central precocious puberty, polycystic ovarian disease, and in vitro fertilization and embryo-transfer programs (IVF-ET) are based on the suppression of gonadotropin secretion (selective medical hypophysectomy) [<CitationRef CitationID="CR6_2">6</CitationRef>, <CitationRef CitationID="CR7_2">7</CitationRef>]. The deprivation of sex hormones induced by chronic administration of LHRH analogs can be used for therapy of hormone-dependent tumors as well as conditions such as leiomyomas and endometriosis. Thus, therapy of breast cancer and prostate cancers is based on reversible medical castration [<CitationRef CitationID="CR6_2">6</CitationRef>, <CitationRef CitationID="CR7_2">7</CitationRef>]. Several LHRH agonists have found important clinical applications in gynecology and oncology. Potent antagonists of LHRH have also been developed [<CitationRef CitationID="CR6_2">6</CitationRef>–<CitationRef CitationID="CR8_2">8</CitationRef>]. Single administration of these competitive LHRH receptor antagonists causes an immediate inhibition of sex steroid secretion [<CitationRef CitationID="CR8_2">8</CitationRef>, <CitationRef CitationID="CR9_2">9</CitationRef>]. The elimination of the potentially dangerous transient increase in circulating sex steroid levels (flare effect) caused by LHRH agonists makes the LHRH antagonists possibly more effective for the treatment of hormone-sensitive cancers [<CitationRef CitationID="CR6_2">6</CitationRef>–<CitationRef CitationID="CR13_2">13</CitationRef>]. LHRH agonists and antagonists can also exert a direct inhibitory effect on various cancer cells and some benign genitourinary tissues through local LHRH receptors. Thus, LHRH antagonists can be used for therapy of benign prostatic hyperplasia (BPH), endometriosis, and leiomyomas. This direct inhibitory effect may contribute to the composite therapeutic effects of LHRH analogs in the treatment of cancer and other conditions [<CitationRef CitationID="CR6_2">6</CitationRef>–<CitationRef CitationID="CR9_2">9</CitationRef>, <CitationRef CitationID="CR13_2">13</CitationRef>, <CitationRef CitationID="CR14_2">14</CitationRef>].
<Figure Category="Standard" Float="Yes" ID="Fig1">
                <Caption Language="En">
                  <CaptionNumber>Fig. 2.1</CaptionNumber>
                  <CaptionContent>
                    <SimplePara>The amino acid sequence of LHRH-I</SimplePara>
                  </CaptionContent>
                </Caption>
                <MediaObject ID="MO1_2">
                  <ImageObject Color="BlackWhite" FileRef="MediaObjects/978-1-60327-829-4_2_Fig1_HTML.gif" Format="GIF" Rendition="HTML" Type="Linedraw"/>
                </MediaObject>
              </Figure>
                  </Para>
            <Para TextBreak="No">In addition to agonists and antagonists, a new class of cytotoxic LHRH analogs has been developed for targeted therapy of cancers expressing LHRH receptors [<CitationRef CitationID="CR15_2">15</CitationRef>–<CitationRef CitationID="CR18_2">18</CitationRef>]. Elevated levels of receptors for LHRH, and other peptides, found on tumor cells, can serve as targets for LHRH analogs linked to cytotoxic agents such as doxorubicin [<CitationRef CitationID="CR6_2">6</CitationRef>, <CitationRef CitationID="CR7_2">7</CitationRef>, <CitationRef CitationID="CR15_2">15</CitationRef>–<CitationRef CitationID="CR18_2">18</CitationRef>]. These analogs thereby can be used as carriers to deliver cytotoxic agents directly to tumors. This direct delivery augments levels of the chemotherapeutic agents in the tumor cells while sparing normal tissues from the toxicity of these drugs. One such carrier hormone used for targeted tumor therapy is the decapeptide [(<Emphasis Type="SmallCaps">D</Emphasis>-Lys<Superscript>6</Superscript>)] LHRH [<CitationRef CitationID="CR6_2">6</CitationRef>, <CitationRef CitationID="CR7_2">7</CitationRef>, <CitationRef CitationID="CR16_2">16</CitationRef>–<CitationRef CitationID="CR18_2">18</CitationRef>].</Para>
            <Para TextBreak="No">We will review some selected endocrine and antitumoral effects of agonists and antagonists of LHRH-I with special reference to treatment of prostate cancer. Anticancer effects of the cytotoxic LHRH analogs will also be discussed. However, a second form of LHRH (LHRH-II), also known as chicken LHRH, that is expressed in the brain and other tissue [<CitationRef CitationID="CR5_2">5</CitationRef>], and its agonists and antagonists will not be discussed because of space limitations as well as because they are not in clinical use, the receptors for LHRH-II being absent in man.</Para>
          </Section1>
          <Section1 ID="Sec2">
            <Heading>Agonists of LHRH</Heading>
            <Para TextBreak="No">In the course of the isolation and synthesis of LHRH-I, in 1971, the work in the laboratory of one of us (AVS) showed that both the natural LHRH-I and synthetic LHRH-I possessed high LH- and FSH-releasing properties [<CitationRef CitationID="CR19_2">19</CitationRef>–<CitationRef CitationID="CR21_2">21</CitationRef>]. The concept that LHRH regulates the secretion of both pituitary gonadotropins, LH and FSH, [<CitationRef CitationID="CR21_2">21</CitationRef>] was confirmed by much experimental and clinical evidence [<CitationRef CitationID="CR1_2">1</CitationRef>, <CitationRef CitationID="CR2_2">2</CitationRef>, <CitationRef CitationID="CR6_2">6</CitationRef>, <CitationRef CitationID="CR7_2">7</CitationRef>, <CitationRef CitationID="CR22_2">22</CitationRef>]. The name gonadotropin-releasing hormone and the abbreviation GnRH likewise proposed by us [<CitationRef CitationID="CR21_2">21</CitationRef>] are used now by many scientists and clinicians [<CitationRef CitationID="CR5_2">5</CitationRef>, <CitationRef CitationID="CR14_2">14</CitationRef>]. However, the abbreviation GnRH leads to confusion with the abbreviation GHRH (growth hormone-releasing hormone) so the use of the original name, LHRH, is favored.</Para>
            <Para TextBreak="No">The half-life of LHRH-I is short; thus, more potent and longer-acting analogs were immediately considered to be essential for clinical applications. The studies on the relationship between structure and biologic activity showed that histidine in position 2 and tryptophan in position 3 play a functional role, and simple substitutions or deletions in this active center decrease or abolish LHRH activity [<CitationRef CitationID="CR13_2">13</CitationRef>, <CitationRef CitationID="CR23_2">23</CitationRef>, <CitationRef CitationID="CR24_2">24</CitationRef>]. However, the tripeptide pyroGlu-His-Trp, or its amide, is inactive. High LHRH activity can be generated by the substitution of these amino acids by structures with similar acid–base and hydrogen-bonding capacity. Amino acids in positions 1 and 4–10 are essential for binding to the receptors and exerting conformational effects [<CitationRef CitationID="CR13_2">13</CitationRef>, <CitationRef CitationID="CR23_2">23</CitationRef>, <CitationRef CitationID="CR24_2">24</CitationRef>]. Substitutions in positions 6 and 10 can produce superactive peptides. Thus, several LHRH analogs substituted in positions 6, 10, or both are much more active than LHRH and also possess protracted activity [<CitationRef CitationID="CR6_2">6</CitationRef>, <CitationRef CitationID="CR13_2">13</CitationRef>, <CitationRef CitationID="CR23_2">23</CitationRef>, <CitationRef CitationID="CR24_2">24</CitationRef>]. Of these, the most important are: [<Emphasis Type="SmallCaps">D</Emphasis>-Trp<Superscript>6</Superscript>]LHRH (Decapeptyl, triptorelin), [<Emphasis Type="SmallCaps">D</Emphasis>-Leu<Superscript>6</Superscript>,Pro<Superscript>9</Superscript>-NHET]LHRH (Leuprolide, Lupron), [<Emphasis Type="SmallCaps">D</Emphasis>-Ser(But)<Superscript>6</Superscript>,Pro<Superscript>9</Superscript>-NHET]LHRH (Buserelin), and [<Emphasis Type="SmallCaps">D</Emphasis>-Ser(But<Superscript>6</Superscript>),Aza-Gly<Superscript>10</Superscript>]LHRH (Zoladex, Goserelin). These agonists are 50–100 times more potent than native LHRH [<CitationRef CitationID="CR6_2">6</CitationRef>, <CitationRef CitationID="CR13_2">13</CitationRef>, <CitationRef CitationID="CR23_2">23</CitationRef>–<CitationRef CitationID="CR27_2">27</CitationRef>]. This greater biological activity of the analogs is due to increased resistance to enzymatic degradation as well as an enhancement in receptor affinity. The substitution of Gly<Superscript>6</Superscript> by <Emphasis Type="SmallCaps">D</Emphasis>-amino acids renders the analog more resistant to degradation by endopeptidases, which split LHRH at this position [<CitationRef CitationID="CR23_2">23</CitationRef>].</Para>
            <Section2 ID="Sec3">
              <Heading>Principles of Oncological and Gynecological Use of LHRH-1 Agonists</Heading>
              <Para TextBreak="No">An acute injection of superactive agonists of LHRH-I induces a marked release of LH and FSH, but paradoxically, chronic administration produces inhibitory effects [<CitationRef CitationID="CR2_2">2</CitationRef>, <CitationRef CitationID="CR4_2">4</CitationRef>–<CitationRef CitationID="CR7_2">7</CitationRef>, <CitationRef CitationID="CR13_2">13</CitationRef>, <CitationRef CitationID="CR23_2">23</CitationRef>–<CitationRef CitationID="CR27_2">27</CitationRef>]. This can be explained by the facts that LHRH secretion is pulsatile and physiologic stimulation of secretion of gonadotropins requires intermittent LHRH release [<CitationRef CitationID="CR6_2">6</CitationRef>]. Continuous stimulation of the pituitary with LHRH-1 or its superactive agonists produces inhibition of hypophyseal–gonadal axis through the process of downregulation (a reduction in the number) of pituitary receptors for LHRH, decrease in expression of LHRH receptor gene, desensitization of the pituitary gonadotrophs, and a suppression of circulating levels of LH, FSH, and sex steroids [<CitationRef CitationID="CR2_2">2</CitationRef>, <CitationRef CitationID="CR4_2">4</CitationRef>–<CitationRef CitationID="CR7_2">7</CitationRef>, <CitationRef CitationID="CR13_2">13</CitationRef>, <CitationRef CitationID="CR23_2">23</CitationRef>, <CitationRef CitationID="CR27_2">27</CitationRef>]. The molecular and cellular basis of the LHRH action on the pituitary and signal transduction pathways of LHRH receptors have been reviewed expertly [<CitationRef CitationID="CR3_2">3</CitationRef>–<CitationRef CitationID="CR5_2">5</CitationRef>]. The cloning of DNA for mouse, rat, and human LHRH type I receptor and the organization of LHRH receptor gene have been reported [<CitationRef CitationID="CR5_2">5</CitationRef>, <CitationRef CitationID="CR28_2">28</CitationRef>, <CitationRef CitationID="CR29_2">29</CitationRef>].</Para>
            </Section2>
            <Section2 ID="Sec4">
              <Heading>Sustained Delivery Systems for LHRH Analogs</Heading>
              <Para TextBreak="No">Initially, agonists of LHRH were administered to patients daily by the subcutaneous (s.c.) route or intranasally [<CitationRef CitationID="CR6_2">6</CitationRef>, <CitationRef CitationID="CR7_2">7</CitationRef>, <CitationRef CitationID="CR13_2">13</CitationRef>]. However, daily administration is inconvenient. Subsequently, long-acting delivery systems for [<Emphasis Type="SmallCaps">D</Emphasis>-Trp<Superscript>6</Superscript>] LHRH (Decapeptyl) and other agonists in microcapsules of poly(<Emphasis Type="SmallCaps">dl</Emphasis>-lactide-co-glycolide) or different polymers were developed [<CitationRef CitationID="CR6_2">6</CitationRef>, <CitationRef CitationID="CR7_2">7</CitationRef>, <CitationRef CitationID="CR13_2">13</CitationRef>, <CitationRef CitationID="CR27_2">27</CitationRef>]. These microcapsules were designed to release a controlled dose of the peptide (usually 100 µg) over a 30-day period. These spherical microcapsules contain 2–6% analog dispersed in biodegradable polymer. Other forms of sustained delivery system consist of microgranules or cylindrical rods containing the peptide analogs.</Para>
              <Para TextBreak="No">For administration, the microcapsules or microgranules are suspended in an injection vehicle containing 2% carboxymethyl cellulose or <Emphasis Type="SmallCaps">d</Emphasis>-Mannitol and 1% Tween 20 or 80 in water and injected i.m. through an18–22 gauge needle [<CitationRef CitationID="CR6_2">6</CitationRef>, <CitationRef CitationID="CR13_2">13</CitationRef>]. Preparations of Decapeptyl and Lupron depot microspheres containing 3.75 mg of peptide injectable i.m., or of Zoladex (Goserelin, 3.6 mg) in cylindrical rods of the polymer poly(<Emphasis Type="SmallCaps">dl</Emphasis>-lactide-co-glycolide) [<CitationRef CitationID="CR13_2">13</CitationRef>, <CitationRef CitationID="CR27_2">27</CitationRef>] injectable s.c. through a 16-gauge needle, and polyhydroxybutyrate tablets containing 3.6–5 mg of Buserelin, which are implantable s.c., have been developed [<CitationRef CitationID="CR6_2">6</CitationRef>]. Improved depot preparations, which release the analogs for 60–180 days have been developed more recently. Six-month depot formulation of leuprolide acetate 22.5 mg (Eligard) and Triptorelin Pamoate (Trelstar LA) containing 11.25 mg of the active drug to be administered every 12 weeks are now available. These formulations release the drugs for several months at the same daily dose as the monthly preparations. There are also implantable devices (Viadur containing 65 mg Leuprolide) for year-long release. Zoladex 3-month implant contains 10.8 mg of Goserelin and is designed for subcutaneous implantation with continuous release over a 12-week period. It is supplied as a 1.5-mm-diameter cylinder, preloaded in a single-use syringe with a 14-gauge needle. Microcapsules and other sustained delivery systems permit the delivery of peptides into the blood stream at a controlled rate over an extended period of time. The agonist Histrelin (Vantas<Superscript>®</Superscript>) has been formulated to deliver the analog for 1 year by using Hydron<Superscript>®</Superscript> technology [<CitationRef CitationID="CR30_2">30</CitationRef>]. The delivery systems developed for administration of LHRH analogs are practical and convenient and ensure patient compliance [<CitationRef CitationID="CR6_2">6</CitationRef>, <CitationRef CitationID="CR13_2">13</CitationRef>].</Para>
            </Section2>
          </Section1>
          <Section1 ID="Sec5">
            <Heading>Antagonistic Analogs of LHRH</Heading>
            <Para TextBreak="No">The concept of modified structures, which exhibit little intrinsic activity, but which can compete with a biologically active ligand for the same receptor sites, has been used to design a number of drugs. The use of LHRH antagonists, instead of agonists, would be indicated in clinical conditions where a prompt and significant inhibition of gonadotropin and/or sex steroid hormones is desired. The development of antagonistic LHRH analogs with required safety and pharmacodynamic characteristics has taken several decades. Since 1972, hundreds of LHRH antagonists have been synthesized and tested [<CitationRef CitationID="CR6_2">6</CitationRef>, <CitationRef CitationID="CR8_2">8</CitationRef>, <CitationRef CitationID="CR13_2">13</CitationRef>, <CitationRef CitationID="CR23_2">23</CitationRef>, <CitationRef CitationID="CR24_2">24</CitationRef>]. Early first-generation LHRH antagonists were hydrophilic and contained replacements or deletions for His in position 2 and Trp in position 3 but had a low potency [<CitationRef CitationID="CR23_2">23</CitationRef>, <CitationRef CitationID="CR24_2">24</CitationRef>]. Later, it was found that the incorporation of a <Emphasis Type="SmallCaps">d</Emphasis>-amino acid in position 6 increased the inhibitory activity of the second-generation antagonists. [<Emphasis Type="SmallCaps">D</Emphasis>-Phe<Superscript>2</Superscript>,<Emphasis Type="SmallCaps">D</Emphasis>-Trp<Superscript>3</Superscript>,<Emphasis Type="SmallCaps">D</Emphasis>-Phe<Superscript>6</Superscript>]LHRH was the first antagonist clinically [<CitationRef CitationID="CR13_2">13</CitationRef>, <CitationRef CitationID="CR23_2">23</CitationRef>, <CitationRef CitationID="CR24_2">24</CitationRef>] active. Insertion of <Emphasis Type="SmallCaps">d</Emphasis>-arginine or related basic residues in position 6 of LHRH antagonists increased the inhibitory activity, but the antagonists of this type induced histamine liberation resulting in transient edema and other anaphylactoid reactions [<CitationRef CitationID="CR13_2">13</CitationRef>, <CitationRef CitationID="CR23_2">23</CitationRef>, <CitationRef CitationID="CR24_2">24</CitationRef>].</Para>
            <Para TextBreak="No">In the third generation of LHRH antagonists, further replacements at positions 1, 10, and other positions were introduced.</Para>
            <Para TextBreak="No">To eliminate the undesirable edematogenic effect, new analogs with neutral <Emphasis Type="SmallCaps">d</Emphasis>-ureidoalky1 amino acids, such as D-Cit at position 6, were synthesized in our laboratory [<CitationRef CitationID="CR31_2">31</CitationRef>]. Among these antagonists devoid of any significant edematogenic effects, [Ac-D-Nal(2)<Superscript>1</Superscript>, D-Phe(4CI)<Superscript>2</Superscript>, D-Pal(3)<Superscript>3</Superscript>, D-Cit<Superscript>6</Superscript>, D-Ala<Superscript>10</Superscript>]-LHRH (Cetrorelix) had the highest inhibitory activity and receptor binding affinity [<CitationRef CitationID="CR6_2">6</CitationRef>, <CitationRef CitationID="CR13_2">13</CitationRef>, <CitationRef CitationID="CR31_2">31</CitationRef>, <CitationRef CitationID="CR32_2">32</CitationRef>].</Para>
            <Para TextBreak="No">Other groups have also reported different structural modifications that preserve high activity and diminish anaphylactoid activity. Antagonists such as antide [N-Ac-D-Nal(2)<Superscript>1</Superscript>, D-Phe(4CI)<Superscript>2</Superscript>, D-Pal(3)<Superscript>3</Superscript>, Lys(Nic)<Superscript>5</Superscript>, D-Lys(Nic)<Superscript>6</Superscript>, Lys(iPr)<Superscript>8</Superscript>, D-Ala<Superscript>10</Superscript>]-LHRH (103) and Nal-Glu antagonist [Ac-D-Nal(2)<Superscript>1</Superscript>, D-Phe(4C1)<Superscript>2</Superscript>, D-Pal(3)<Superscript>3</Superscript>, Arg<Superscript>5</Superscript>, D-Glu<Superscript>6</Superscript>(AA), D-Ala<Superscript>10</Superscript>]-LHRH were also potent, although antide had low solubility and Nal-Glu antagonist caused some clinical side effects [<CitationRef CitationID="CR13_2">13</CitationRef>]. Other LHRH antagonists that were developed included Azaline B [Ac-D-Nal(2)<Superscript>1</Superscript>, D-Phe(4C1)<Superscript>2</Superscript>, D-Pal(3)l<Superscript>3</Superscript>, Aph<Superscript>5</Superscript>(Atz), Aph<Superscript>6</Superscript>(Atz), Ilys<Superscript>8</Superscript>, D-Ala<Superscript>10</Superscript>]-LHRH, Ganirelix [N-Ac-D-Nal(2)<Superscript>1</Superscript>, D-p-C1-Phe<Superscript>2</Superscript>, D-Pal(3)<Superscript>3</Superscript>, D-hArg(Et<Subscript>2</Subscript>)<Superscript>6</Superscript>, L-hArg(Et<Subscript>2</Subscript>)<Superscript>8</Superscript>, D-A1a<Superscript>10</Superscript>]-LHRH [<CitationRef CitationID="CR33_2">33</CitationRef>], and Abarelix [N-Ac-D-Nal(2)-D-(p-C1-Phe)-D-Pal(3)-Ser-NMeTyr-Asn-Leu-Ilys-Pro-Gly-NH<Subscript>2</Subscript>] [<CitationRef CitationID="CR34_2">34</CitationRef>]. These compounds inhibited ovulation in rats at low doses (1–5 μg), were devoid of edematogenic side effects, and on chronic administration to rats induced a reversible suppression in the circulating level of sex steroids [<CitationRef CitationID="CR31_2">31</CitationRef>, <CitationRef CitationID="CR35_2">35</CitationRef>].</Para>
            <Para TextBreak="No">Recently, a new powerful LHRH antagonist, Degarelix, with a high therapeutic index, and its various analogs were synthesized [<CitationRef CitationID="CR36_2">36</CitationRef>] and evaluated experimentally in vivo and in vitro as well as clinically [<CitationRef CitationID="CR37_2">37</CitationRef>]. Its chemical structure is: <Emphasis Type="Italic">N</Emphasis>-acetyl-3(naphtalen-2-yl)-<Emphasis Type="SmallCaps">D</Emphasis>-alanyl-4-chloro-<Emphasis Type="SmallCaps">D</Emphasis>-phenylalanyl-3-(pyridin-3-yl)-<Emphasis Type="SmallCaps">D</Emphasis>-alanyl-<Emphasis Type="SmallCaps">L</Emphasis>-seryl-4((((4S)-2,6-dioxohexahydropyrimidin-4-yl)carbonyl)amino)-<Emphasis Type="SmallCaps">L</Emphasis>-phenylalanyl- 4-(carbamoylamino)-<Emphasis Type="SmallCaps">D</Emphasis>-phenylalanyl-<Emphasis Type="SmallCaps">L</Emphasis>-leucyl-N6-(1-methylethyl)-<Emphasis Type="SmallCaps">L</Emphasis>-lysyl-<Emphasis Type="SmallCaps">L</Emphasis>-prolyl-<Emphasis Type="SmallCaps">D</Emphasis>-alaninamide [<CitationRef CitationID="CR36_2">36</CitationRef>, <CitationRef CitationID="CR37_2">37</CitationRef>].</Para>
            <Para TextBreak="No">The antagonist cetrorelix first made in our laboratory [<CitationRef CitationID="CR6_2">6</CitationRef>, <CitationRef CitationID="CR7_2">7</CitationRef>, <CitationRef CitationID="CR13_2">13</CitationRef>, <CitationRef CitationID="CR31_2">31</CitationRef>, <CitationRef CitationID="CR32_2">32</CitationRef>] and later developed for clinical use by Asta-Medica, then Zentaris, Frankfurt, Germany, and Ganirelix [<CitationRef CitationID="CR33_2">33</CitationRef>] (Syntex Research), and Abarelix (Praecis Pharmaceuticals), USA [<CitationRef CitationID="CR34_2">34</CitationRef>] were shown to be safe and effective in patients and have already been useful in clinical practice [<CitationRef CitationID="CR38_2">38</CitationRef>]. Because parenteral administration of peptide LHRH antagonists may be inconvenient for some patients, nonpeptide antagonists that can be given orally were also recently developed [<CitationRef CitationID="CR39_2">39</CitationRef>].</Para>
            <Section2 ID="Sec6">
              <Heading>Principles of Gynecological and Oncological Use of LHRH Antagonists</Heading>
              <Section3 ID="Sec7">
                <Heading>Effects on the Pituitary LHRH Receptors</Heading>
                <Para TextBreak="No">Because native LHRH stimulates the secretion of both gonadotropins, LHRH antagonists were expected to inhibit the release of both LH and FSH. While the inhibitory effect of LHRH antagonists on LH is immediate in onset, however, that on the FSH is not as instantaneous [<CitationRef CitationID="CR10_2">10</CitationRef>–<CitationRef CitationID="CR12_2">12</CitationRef>, <CitationRef CitationID="CR40_2">40</CitationRef>]. A single injection of an LHRH antagonist at a high dose causes an immediate and long-lasting suppression of serum LH and a smaller and delayed decrease in the FSH levels [<CitationRef CitationID="CR10_2">10</CitationRef>–<CitationRef CitationID="CR12_2">12</CitationRef>, <CitationRef CitationID="CR40_2">40</CitationRef>]. Thus, in rats, LHRH antagonists are not able to completely block the release of FSH in vivo, and other mechanisms may contribute to the regulation of FSH secretion. However, extensive clinical findings indicate that chronic treatment with LHRH antagonists at high doses results in a profound decrease in both LH and FSH as well as a reduction in sex steroid hormone levels [<CitationRef CitationID="CR6_2">6</CitationRef>–<CitationRef CitationID="CR9_2">9</CitationRef>, <CitationRef CitationID="CR32_2">32</CitationRef>].</Para>
                <Para TextBreak="No">The receptor mechanisms through which the LHRH antagonists suppress LH and FSH release were elucidated in the laboratory of one of us [<CitationRef CitationID="CR35_2">35</CitationRef>, <CitationRef CitationID="CR41_2">41</CitationRef>–<CitationRef CitationID="CR44_2">44</CitationRef>]. In our initial study [<CitationRef CitationID="CR41_2">41</CitationRef>], male rats were implanted subcutaneously with osmotic minipumps releasing Cetrorelix. The treatment with Cetrorelix reduced serum LH and testosterone levels, but 90 days after cessation of treatment, LH and testosterone returned to control levels [<CitationRef CitationID="CR41_2">41</CitationRef>]. Immediately after the discontinuation of Cetrorelix, a significant downregulation of the pituitary LHRH receptors was found, but 90 days later, this phenomenon was reversed [<CitationRef CitationID="CR41_2">41</CitationRef>]. These findings indicate that the recovery of hormonal levels parallels the return of pituitary LHRH receptor numbers to normal values [<CitationRef CitationID="CR41_2">41</CitationRef>].</Para>
                <Para TextBreak="No">In another investigation, a single subcutaneous administration of a large dose of Cetrorelix to male rats suppressed serum testosterone and LH levels and produced a significant downregulation of binding sites for LHRH 7 days after administration, but a complete recovery in LHRH receptor levels occurred within 60 days [<CitationRef CitationID="CR42_2">42</CitationRef>].</Para>
                <Para TextBreak="No">To determine if the treatment with Cetrorelix affects the concentration of measurable LHRH binding sites, we used an in vitro method for desaturation of receptors based on chaotropic agents such as NH<Subscript>4</Subscript>SCN [<CitationRef CitationID="CR43_2">43</CitationRef>]. Six hours after the administration of Cetrorelix, occupied LHRH receptors represented only 10% of total receptors, but later, no occupied receptors could be detected. Receptor assays carried out after desaturation of LHRH binding sites demonstrated that pituitary LHRH receptors in rats were significantly downregulated for at least 72 h after the administration of Cetrorelix [<CitationRef CitationID="CR43_2">43</CitationRef>]. The downregulation of LHRH binding sites induced by Cetrorelix was accompanied by suppression of serum LH and testosterone. These results demonstrate that the LHRH antagonist Cetrorelix produces a clear downregulation of pituitary receptors for LHRH and not merely an occupancy of binding sites [<CitationRef CitationID="CR43_2">43</CitationRef>].</Para>
                <Para TextBreak="No">In another study [<CitationRef CitationID="CR44_2">44</CitationRef>], we treated one group of male rats daily for 4 weeks with Cetrorelix. Another group of rats received a single intramuscular injection of 4.5 mg of depot Cetrorelix pamoate. An intravenous stimulation test with LHRH was performed after 4 weeks of treatment [<CitationRef CitationID="CR44_2">44</CitationRef>]. LHRH-stimulated LH secretion at 30 min was completely suppressed in rats treated with either regimen of Cetrorelix. The concentration of pituitary receptors for LHRH was reduced in both Cetrorelix treated groups by 77–82%. Depot Cetrorelix pamoate also led to a 75–80% decrease in the levels of mRNA for pituitary LHRH receptors [<CitationRef CitationID="CR44_2">44</CitationRef>]. These results demonstrate that administration of the LHRH antagonist Cetrorelix causes a marked decrease in the levels of LHRH receptors and in the expression of the LHRH receptor gene [<CitationRef CitationID="CR44_2">44</CitationRef>].</Para>
                <Para TextBreak="No">Using Cetrorelix at high doses in vivo in ovariectomized rats as well as in vitro in the superfused pituitary cell system, we demonstrated that LHRH antagonists, in addition to the blockade of the pituitary LHRH receptors downregulate the mRNA expression for the LHRH receptors indirectly, by counteracting the stimulatory effect of endogenous LHRH [<CitationRef CitationID="CR10_2">10</CitationRef>–<CitationRef CitationID="CR12_2">12</CitationRef>]. Thus, in the rat pituitary cell system in vitro, which is devoid of LHRH, Cetrorelix caused no change in the gene expression of the pituitary LHRH receptors [<CitationRef CitationID="CR10_2">10</CitationRef>, <CitationRef CitationID="CR11_2">11</CitationRef>]. However, when Cetrorelix was used in vivo at low doses, it suppressed the pituitary–gonadal axis only by a competitive receptor blockade but no downregulation of the LHRH receptors occurred [<CitationRef CitationID="CR12_2">12</CitationRef>].</Para>
              </Section3>
            </Section2>
            <Section2 ID="Sec8">
              <Heading>Clinical Findings</Heading>
              <Para TextBreak="No">Extensive clinical data indicate that a downregulation of pituitary receptors occurs in a clinical setting under a variety of conditions after the administration of agonistic analogs of LHRH [<CitationRef CitationID="CR6_2">6</CitationRef>, <CitationRef CitationID="CR13_2">13</CitationRef>]. Some clinical results suggest that LHRH antagonists may also lead to pituitary downregulation. Behre and coworkers [<CitationRef CitationID="CR45_2">45</CitationRef>] injected men with a loading dose of 10 mg of Cetrorelix for 5 days followed by administration of 1–2 mg of Cetrorelix once or twice daily for 3 weeks. Initial administration of Cetrorelix suppressed serum levels of LH, FSH, and testosterone, and this reduction was maintained during the low-dose maintenance therapy in all groups [<CitationRef CitationID="CR45_2">45</CitationRef>]. In comparison with the first week, lower levels of LH, FSH, and testosterone were detected during the second and third weeks [<CitationRef CitationID="CR45_2">45</CitationRef>]. Observation that low doses of LHRH antagonist, which are ineffective initially can suppress gonadotropins effectively during subsequent treatment suggest that LHRH antagonists produce receptor downregulation in addition to competitive receptor occupancy [<CitationRef CitationID="CR45_2">45</CitationRef>].</Para>
            </Section2>
            <Section2 ID="Sec9">
              <Heading>Receptors for LHRH Type I on Tumors</Heading>
              <Para TextBreak="No">Besides their actions on the pituitary, LHRH agonists and antagonists exert direct effects on tumor cells [<CitationRef CitationID="CR6_2">6</CitationRef>, <CitationRef CitationID="CR13_2">13</CitationRef>]. The evidence for direct action of LHRH analogs on tumors is based on the detection of high-affinity binding sites for LHRH in various cancers, the inhibitory effects of analogs on tumor cell lines in cultures [<CitationRef CitationID="CR6_2">6</CitationRef>, <CitationRef CitationID="CR13_2">13</CitationRef>], and clinical findings. Receptors for LHRH have been found in various rodent and human cancers [<CitationRef CitationID="CR6_2">6</CitationRef>, <CitationRef CitationID="CR13_2">13</CitationRef>]. Binding sites for LHRH and the expression of mRNA for LHRH receptors have been detected in specimens of human prostate cancer [<CitationRef CitationID="CR46_2">46</CitationRef>–<CitationRef CitationID="CR48_2">48</CitationRef>] and prostate cancer lines [<CitationRef CitationID="CR46_2">46</CitationRef>, <CitationRef CitationID="CR49_2">49</CitationRef>, <CitationRef CitationID="CR50_2">50</CitationRef>]. Various investigators have reported the presence of LHRH receptors in human mammary carcinoma cell lines [<CitationRef CitationID="CR51_2">51</CitationRef>, <CitationRef CitationID="CR52_2">52</CitationRef>]. We found high-affinity LHRH binding sites in 52% of human breast cancer specimen [<CitationRef CitationID="CR53_2">53</CitationRef>]. LHRH receptors were similarly detected in about 80% of human ovarian epithelial cancer samples, in ovarian cancer lines [<CitationRef CitationID="CR54_2">54</CitationRef>, <CitationRef CitationID="CR55_2">55</CitationRef>], in nearly 80% of human endometrial carcinomas [<CitationRef CitationID="CR56_2">56</CitationRef>], and in endometrial cancer lines [<CitationRef CitationID="CR54_2">54</CitationRef>, <CitationRef CitationID="CR57_2">57</CitationRef>]. The expression of LHRH receptor gene in human breast, endometrial, ovarian tumors, and the respective cancer cell lines was also demonstrated by reverse transcription-polymerase chain reaction (RT-PCR) [<CitationRef CitationID="CR58_2">58</CitationRef>–<CitationRef CitationID="CR61_2">61</CitationRef>]. In addition, LHRH receptors were also demonstrated in surgical specimens of human renal cell carcinomas, lymphomas, and melanomas by immunohistochemistry and/or RT-PCR [<CitationRef CitationID="CR32_2">32</CitationRef>, <CitationRef CitationID="CR57_2">57</CitationRef>]. LHRH receptors on human cancers appear to be similar to pituitary LHRH receptors [<CitationRef CitationID="CR28_2">28</CitationRef>]. These results provide a rationale for the use of targeted cytotoxic LHRH analogs in malignancies in which receptors for LHRH are expressed [<CitationRef CitationID="CR15_2">15</CitationRef>, <CitationRef CitationID="CR16_2">16</CitationRef>, <CitationRef CitationID="CR18_2">18</CitationRef>]. In addition, the presence of receptors for LHRH on tumors may expound the effect of LHRH analogs seen in vitro and occasional responses to LHRH agonists in postmenopausal women with breast cancer [<CitationRef CitationID="CR6_2">6</CitationRef>].</Para>
            </Section2>
            <Section2 ID="Sec10">
              <Heading>Direct Effects of LHRH Analogs on Tumors</Heading>
              <Para TextBreak="No">LHRH analogs can exert direct effects on prostate, breast, ovarian, endometrial and other cancers mediated through specific LHRH receptors on tumor cells [<CitationRef CitationID="CR5_2">5</CitationRef>–<CitationRef CitationID="CR7_2">7</CitationRef>, <CitationRef CitationID="CR13_2">13</CitationRef>, <CitationRef CitationID="CR14_2">14</CitationRef>, <CitationRef CitationID="CR46_2">46</CitationRef>, <CitationRef CitationID="CR49_2">49</CitationRef>, <CitationRef CitationID="CR51_2">51</CitationRef>, <CitationRef CitationID="CR52_2">52</CitationRef>, <CitationRef CitationID="CR58_2">58</CitationRef>, <CitationRef CitationID="CR61_2">61</CitationRef>, <CitationRef CitationID="CR62_2">62</CitationRef>]. Inhibition of growth of cultured tumor cells by LHRH analogs supports the view of their direct effects. Suppression of human mammary, ovarian, endometrial, and prostatic cancer cell lines by LHRH agonists and LHRH antagonists, such as Cetrorelix in vitro, is now well documented [<CitationRef CitationID="CR6_2">6</CitationRef>, <CitationRef CitationID="CR7_2">7</CitationRef>, <CitationRef CitationID="CR13_2">13</CitationRef>, <CitationRef CitationID="CR51_2">51</CitationRef>, <CitationRef CitationID="CR52_2">52</CitationRef>, <CitationRef CitationID="CR58_2">58</CitationRef>, <CitationRef CitationID="CR61_2">61</CitationRef>, <CitationRef CitationID="CR63_2">63</CitationRef>]. These results suggest a regulatory role for LHRH in tumor growth. The production of an LHRH-like peptide or expression of mRNA for LHRH was demonstrated in human prostatic, mammary, endometrial, and ovarian cancer lines, suggesting that local LHRH may be involved in the growth of these tumors [<CitationRef CitationID="CR6_2">6</CitationRef>, <CitationRef CitationID="CR7_2">7</CitationRef>, <CitationRef CitationID="CR49_2">49</CitationRef>, <CitationRef CitationID="CR50_2">50</CitationRef>, <CitationRef CitationID="CR64_2">64</CitationRef>]. The existence of functional regulatory LHRH loops in prostate cancer and ovarian cancer has also been postulated [<CitationRef CitationID="CR49_2">49</CitationRef>, <CitationRef CitationID="CR50_2">50</CitationRef>, <CitationRef CitationID="CR64_2">64</CitationRef>].</Para>
            </Section2>
            <Section2 ID="Sec11">
              <Heading>Mechanism of Action of LHRH-I and Its Analogs</Heading>
              <Para TextBreak="No">The actions of LHRH-I are mediated by type I LHRH receptors localized on the plasma membranes of the pituitary gonadotrophs [<CitationRef CitationID="CR3_2">3</CitationRef>–<CitationRef CitationID="CR5_2">5</CitationRef>, <CitationRef CitationID="CR13_2">13</CitationRef>, <CitationRef CitationID="CR58_2">58</CitationRef>]. The initial step in the action of LHRH is the binding to its receptors [<CitationRef CitationID="CR3_2">3</CitationRef>, <CitationRef CitationID="CR4_2">4</CitationRef>, <CitationRef CitationID="CR65_2">65</CitationRef>]. The binding causes a microaggregation of receptors and complex formation. The complex formed is then internalized and degraded [<CitationRef CitationID="CR3_2">3</CitationRef>, <CitationRef CitationID="CR4_2">4</CitationRef>, <CitationRef CitationID="CR65_2">65</CitationRef>]. In the pituitary, the LHRH receptors are coupled to G proteins (αq) that activate phospholipase C, which leads to the production of inositol phosphates and diacylglycerol [<CitationRef CitationID="CR3_2">3</CitationRef>, <CitationRef CitationID="CR4_2">4</CitationRef>]. This process induces Ca++ mobilization and activation of protein kinase C, resulting in the release of LH and FSH. However in cancers, after binding of the ligand, the LHRH receptors couple to G protein αi and activate a phosphotyrosine phosphatase [<CitationRef CitationID="CR58_2">58</CitationRef>, <CitationRef CitationID="CR61_2">61</CitationRef>, <CitationRef CitationID="CR66_2">66</CitationRef>–<CitationRef CitationID="CR69_2">69</CitationRef>], which dephosphorylates epidermal growth factor (EGF) receptors. Thus, mitogenic signaling induced by binding of EGF to its receptor is abolished leading to an inhibition of mitogen-activated protein kinase (MAPK) [<CitationRef CitationID="CR58_2">58</CitationRef>, <CitationRef CitationID="CR61_2">61</CitationRef>] and EGF-induced proliferation [<CitationRef CitationID="CR58_2">58</CitationRef>, <CitationRef CitationID="CR61_2">61</CitationRef>]. The signaling mechanism of type I LHRH receptor has been reviewed extensively [<CitationRef CitationID="CR3_2">3</CitationRef>–<CitationRef CitationID="CR5_2">5</CitationRef>, <CitationRef CitationID="CR58_2">58</CitationRef>, <CitationRef CitationID="CR61_2">61</CitationRef>, <CitationRef CitationID="CR65_2">65</CitationRef>, <CitationRef CitationID="CR68_2">68</CitationRef>].</Para>
            </Section2>
            <Section2 ID="Sec12">
              <Heading>Clinical Applications of LHRH Antagonists</Heading>
              <Para TextBreak="No">LHRH antagonists can be used in clinical conditions when suppression of endogenous gonadotropin/sex steroid levels is indicated. The applications of LHRH antagonists include the treatment of nonmalignant tumorous conditions such as endometriosis, and leiomyomas [<CitationRef CitationID="CR70_2">70</CitationRef>], central precocious puberty [<CitationRef CitationID="CR71_2">71</CitationRef>], as well as of BPH, and breast, ovarian, and prostatic cancers [<CitationRef CitationID="CR6_2">6</CitationRef>, <CitationRef CitationID="CR7_2">7</CitationRef>, <CitationRef CitationID="CR13_2">13</CitationRef>, <CitationRef CitationID="CR32_2">32</CitationRef>, <CitationRef CitationID="CR57_2">57</CitationRef>, <CitationRef CitationID="CR70_2">70</CitationRef>, <CitationRef CitationID="CR72_2">72</CitationRef>–<CitationRef CitationID="CR76_2">76</CitationRef>]. Another important application is the prevention of premature LH surge in protocols for controlled ovarian stimulation (COS) for assisted reproductive technology (ART) used for IVF-ET [<CitationRef CitationID="CR8_2">8</CitationRef>, <CitationRef CitationID="CR9_2">9</CitationRef>, <CitationRef CitationID="CR38_2">38</CitationRef>]. At this time, LHRH antagonists are approved for the use in COS-ART and are in phase III trials for BPH. The applications for endometriosis and myomas have approval pending.</Para>
            </Section2>
            <Section2 ID="Sec13">
              <Heading>Use of LHRH Antagonists in BPH</Heading>
              <Para TextBreak="No">LHRH antagonists should be beneficial for patients with BPH since the decrease in testosterone levels by LHRH agonists and antagonists leads to reduction in prostate size. However, the effects of LHRH agonists on BPH are only transient [<CitationRef CitationID="CR32_2">32</CitationRef>, <CitationRef CitationID="CR57_2">57</CitationRef>, <CitationRef CitationID="CR71_2">71</CitationRef>–<CitationRef CitationID="CR76_2">76</CitationRef>].</Para>
              <Para TextBreak="No">Several studies and clinical trials [<CitationRef CitationID="CR74_2">74</CitationRef>–<CitationRef CitationID="CR76_2">76</CitationRef>] have documented that therapy with LHRH antagonist Cetrorelix causes a marked and long-lasting improvement in lower urinary tract symptoms (LUTS) in men with symptomatic BPH without impairment of gonadal function [<CitationRef CitationID="CR74_2">74</CitationRef>–<CitationRef CitationID="CR76_2">76</CitationRef>]. This improvement, including the lowering of international prostate symptom score (IPSS), reduction in prostate volume, and increase in urinary peak flow rate, appears to be superior to that achieved with alpha-blockers or 5-alpha-reductase inhibitors. Low doses of Cetrorelix used in current clinical trials cause only a temporary downregulation of pituitary receptors for LHRH and a partial suppression of pituitary–gonadal axis and testosterone levels [<CitationRef CitationID="CR32_2">32</CitationRef>, <CitationRef CitationID="CR57_2">57</CitationRef>, <CitationRef CitationID="CR77_2">77</CitationRef>]. The improvement in LUTS could be due to direct inhibitory effects of Cetrorelix on the prostate exerted through prostatic LHRH receptors and possible alterations in levels of growth factors. Thus, Cetrorelix appears to reduce various growth factors in the prostate, and in doses which, do not induce castration levels of testosterone, can lower prostate weights. Experimental and clinical studies with LHRH agonists, antagonist, and cytotoxic analogs in prostate cancer will be described separately.</Para>
            </Section2>
            <Section2 ID="Sec14">
              <Heading>Targeted Cytotoxic LHRH Analogs</Heading>
              <Para TextBreak="No">Targeted chemotherapy represents a modern oncological approach designed to improve the effectiveness of cytotoxic drugs and decrease peripheral toxicity. The first concept of targeted therapy, so-called <Emphasis Type="Italic">Magic Bullets</Emphasis>, was proposed by Paul Ehrich more than 100 years ago (for review see [<CitationRef CitationID="CR15_2">15</CitationRef>]). However, this approach remained unexplored for many decades. In the early 1990s, we put forward the hypothesis that the receptors for peptide hormones on tumor cells could serve as targets for peptide ligands linked to various cytotoxic agents [<CitationRef CitationID="CR15_2">15</CitationRef>]. On the basis of the presence of specific receptors for LHRH on tumor cells, we developed a new class of targeted antitumor agents by linking cytotoxic radicals to analogs of LHRH and other peptides [<CitationRef CitationID="CR15_2">15</CitationRef>–<CitationRef CitationID="CR18_2">18</CitationRef>].</Para>
              <Para TextBreak="No">Therapy with targeted cytotoxic analog therapy can produce an accumulation of the cytotoxic agent in the cancer cells, thus producing a localized cytocidal effect and reducing peripheral toxicity [<CitationRef CitationID="CR7_2">7</CitationRef>, <CitationRef CitationID="CR13_2">13</CitationRef>, <CitationRef CitationID="CR15_2">15</CitationRef>–<CitationRef CitationID="CR18_2">18</CitationRef>, <CitationRef CitationID="CR50_2">50</CitationRef>, <CitationRef CitationID="CR78_2">78</CitationRef>–<CitationRef CitationID="CR80_2">80</CitationRef>]. Our early conjugates contained cisplatin, methotrexate, or melphalan [<CitationRef CitationID="CR15_2">15</CitationRef>]. Later, we developed much more potent LHRH analogs containing doxorubicin or its derivatives [<CitationRef CitationID="CR80_2">80</CitationRef>]. In the targeted cytotoxic LHRH analog, AN-152, doxorubicin hemiglutarate was coupled to the agonist [<Emphasis Type="SmallCaps">D</Emphasis>-Lys<Superscript>6</Superscript>] LHRH. Another targeted cytotoxic LHRH analog, AN-207, contained (2-pyrrolino)-doxorubicin (AN-201) coupled to the same [D-Lys<Superscript>6</Superscript>] LHRH carrier. Both cytotoxic analogs preserved high binding affinity of the [D-Lys<Superscript>6</Superscript>] LHRH to LHRH receptors and the powerful cytocidal activity of the cytotoxic agent [<CitationRef CitationID="CR13_2">13</CitationRef>, <CitationRef CitationID="CR79_2">79</CitationRef>] and exhibited a high antitumor activity in various experimental cancer models [<CitationRef CitationID="CR15_2">15</CitationRef>–<CitationRef CitationID="CR18_2">18</CitationRef>, <CitationRef CitationID="CR32_2">32</CitationRef>, <CitationRef CitationID="CR57_2">57</CitationRef>]. Other groups developed different types of cytotoxic LHRH analogs by designing LHRH-containing chimeric toxic protein complexes, which were effective against various cancers [<CitationRef CitationID="CR81_2">81</CitationRef>].</Para>
              <Para TextBreak="No">Cytotoxic LHRH analogs are internalized by rat pituitary cells as well as by human ovarian, endometrial, and breast cancer cells [<CitationRef CitationID="CR17_2">17</CitationRef>, <CitationRef CitationID="CR18_2">18</CitationRef>]. The binding of AN-152 to the LHRH receptors, its entry into the cells, and its localization in the cytoplasm, followed by appearance in the nucleus were demonstrated by confocal laser scanning microscopy and by coupling a two-photon-emitting fluorophore to the compound [<CitationRef CitationID="CR17_2">17</CitationRef>, <CitationRef CitationID="CR18_2">18</CitationRef>, <CitationRef CitationID="CR82_2">82</CitationRef>, <CitationRef CitationID="CR83_2">83</CitationRef>]. The internalization process depends on the presence of LHRH receptors on cells since it does not occur in cancer cells, which do not express LHRH receptors [<CitationRef CitationID="CR18_2">18</CitationRef>].</Para>
            </Section2>
            <Section2 ID="Sec15">
              <Heading>LHRH Agonists in Therapy of Prostate Cancer</Heading>
              <Para TextBreak="No">LHRH agonists have had a great therapeutic impact on treatment of prostate cancer [<CitationRef CitationID="CR6_2">6</CitationRef>, <CitationRef CitationID="CR7_2">7</CitationRef>]. Carcinoma of the prostate is the most common noncutaneous malignancy in the American male and is the second leading cause of cancer-related deaths among men [<CitationRef CitationID="CR6_2">6</CitationRef>, <CitationRef CitationID="CR72_2">72</CitationRef>]. About 70% of human prostate cancers are androgen dependent [<CitationRef CitationID="CR6_2">6</CitationRef>, <CitationRef CitationID="CR72_2">72</CitationRef>]. The therapy of advanced prostate cancer is based on the androgen dependence of the tumor. Previous therapies included orchiectomy and administration of estrogens [<CitationRef CitationID="CR6_2">6</CitationRef>, <CitationRef CitationID="CR72_2">72</CitationRef>, <CitationRef CitationID="CR84_2">84</CitationRef>]. However, surgical castration is associated with a psychological impact, and diethylstilbestrol has serious cardiovascular, hepatic, and mammotropic side effects. About 27 years ago, we introduced a new endocrine therapy for advanced prostate cancer based on the use of agonistic analogs of LHRH [<CitationRef CitationID="CR85_2">85</CitationRef>, <CitationRef CitationID="CR86_2">86</CitationRef>]. Medical castration produced by chronic administration of LHRH analogs accounts for most therapeutic benefits derived from this therapy [<CitationRef CitationID="CR6_2">6</CitationRef>, <CitationRef CitationID="CR72_2">72</CitationRef>, <CitationRef CitationID="CR84_2">84</CitationRef>–<CitationRef CitationID="CR86_2">86</CitationRef>], but LHRH agonists and antagonists also exert direct effects on prostate tumor cells [<CitationRef CitationID="CR6_2">6</CitationRef>, <CitationRef CitationID="CR72_2">72</CitationRef>].</Para>
              <Para TextBreak="No">First, in our experimental studies, we demonstrated that chronic administration of the agonist [D-Trp<Superscript>6</Superscript>] LHRH reduced serum levels of LH, FSH, and testosterone and suppressed tumor growth in rats with Dunning R-3327-H prostate cancers [<CitationRef CitationID="CR85_2">85</CitationRef>]. This demonstration led to clinical trials. The efficacy of palliative therapy with the agonistic analog of LHRH in men with advanced prostate cancer was first shown in 1980–1981 in collaboration with Tolis et al. [<CitationRef CitationID="CR86_2">86</CitationRef>] in a clinical trial in Montreal. Our study revealed a fall in testosterone levels and marked subjective and objective improvement in patients with advanced prostate carcinoma after therapy with agonistic LHRH analogs, Decapeptyl and Buserelin [<CitationRef CitationID="CR86_2">86</CitationRef>]. These results were confirmed and extended by further clinical trials with LHRH agonists in patients with prostate cancer [<CitationRef CitationID="CR6_2">6</CitationRef>, <CitationRef CitationID="CR72_2">72</CitationRef>, <CitationRef CitationID="CR87_2">87</CitationRef>]. The LHRH analogs used clinically for therapy of advanced prostate cancer include Decapeptyl, Buserelin, Leuprolide, and Zoladex [<CitationRef CitationID="CR6_2">6</CitationRef>, <CitationRef CitationID="CR72_2">72</CitationRef>, <CitationRef CitationID="CR87_2">87</CitationRef>]. Initially, agonists of LHRH were given daily by the s.c. or even intranasal route. Subsequently, we developed a long-acting delivery system for Decapeptyl based on microcapsules designed to release 100 µg/day of the peptide over a 30-day period [<CitationRef CitationID="CR6_2">6</CitationRef>, <CitationRef CitationID="CR72_2">72</CitationRef>] after the i.m. injection of 3.7 mg of the analog in these microcapsules. The efficacy of the slow-release formulation of microcapsules of LHRH agonists in the treatment of advanced prostatic carcinoma was documented in clinical trials [<CitationRef CitationID="CR6_2">6</CitationRef>, <CitationRef CitationID="CR72_2">72</CitationRef>] Development of microcapsules and other sustained-release formulations, such as implants that can be administered periodically, made the treatment of patients with prostate cancer more convenient, and efficacious [<CitationRef CitationID="CR6_2">6</CitationRef>].</Para>
              <Para TextBreak="No">Treatment with agonists of LHRH is now also recommended in men with a rising prostate-specific antigen (PSA) level after surgery or radiotherapy. LHRH agonists can be also used in combination with an antiandrogen prior to radical prostatectomy or at the beginning of external-beam radiotherapy. Intermittent therapy with LHRH agonists may improve the quality of life in patients with prostate cancer. The therapy with agonists of LHRH is presently the preferred method of treatment for men with advanced prostate cancer, and in ≈70% of cases, LHRH agonists are selected for primary treatment [<CitationRef CitationID="CR6_2">6</CitationRef>].</Para>
              <Para TextBreak="No">Side effects caused by chronic administration of LHRH agonists include impotence, loss of libido, and hot flushes and are due to androgen deprivation. An occasional “flare” in the disease with an increase in bone pain in the first few days after administration of LHRH agonists has been reported in ≈10–20% of patients [<CitationRef CitationID="CR6_2">6</CitationRef>, <CitationRef CitationID="CR72_2">72</CitationRef>, <CitationRef CitationID="CR87_2">87</CitationRef>]. This flare can be prevented by pretreatment with antiandrogens. Long-term androgen deprivation therapy may also be associated with osteoporosis and an increased incidence of cardiovascular disease and diabetes.</Para>
              <Para TextBreak="No">Total androgen blockade is based on the use of a combination of LHRH agonist with antiandrogen for the treatment of prostate cancer. Combinations of LHRH agonists with antiandrogens, such as nilutamide, bicalutamide, or flutamide, are used clinically [<CitationRef CitationID="CR88_2">88</CitationRef>]. The benefits of this combination are still controversial as antiandrogens are expensive and may be toxic to the liver. Moreover, the combination of LHRH agonists and antiandrogen cannot prevent an eventual relapse.</Para>
            </Section2>
            <Section2 ID="Sec16">
              <Heading>Use of LHRH Antagonists in Prostate Cancer</Heading>
              <Para TextBreak="No">The use of LHRH antagonists would avoid the temporary clinical “flare” of the disease that can occur in ≈10–20% of prostate cancer patients when the LHRH agonists are given as single agents [<CitationRef CitationID="CR6_2">6</CitationRef>, <CitationRef CitationID="CR88_2">88</CitationRef>]. We first investigated inhibitory effects of the antagonist Cetrorelix on the growth of experimental prostate cancers in rats bearing Dunning R-3327-H prostate carcinoma. Cetrorelix caused a greater inhibition of prostate cancer growth than [D-Trp<Superscript>6</Superscript>]LHRH [<CitationRef CitationID="CR72_2">72</CitationRef>]. We also treated male nude mice bearing xenografts of human androgen-dependent prostate adenocarcinoma PC-82 with microcapsules of the agonist [D-Trp<Superscript>6</Superscript>]LHRH or microgranules of Cetrorelix. Cetrorelix, again caused a greater decrease in tumor weight and volume [<CitationRef CitationID="CR72_2">72</CitationRef>], induced more enhanced apoptosis in prostate tumors, and lowered serum levels of testosterone and PSA better than the LHRH agonist. These studies demonstrated the efficacy of Cetrorelix in inhibiting growth of androgen-dependent prostate cancers [<CitationRef CitationID="CR72_2">72</CitationRef>].</Para>
              <Para TextBreak="No">Clinical trials demonstrated that an inhibition of testosterone and PSA levels and a decrease in prostate size are achieved in patients with advanced prostatic cancer treated with the antagonist Cetrorelix [<CitationRef CitationID="CR74_2">74</CitationRef>]. In the first study, the responses to 500 µg of Cetrorelix given b.i.d. were evaluated in patients with advanced prostatic cancer [<CitationRef CitationID="CR74_2">74</CitationRef>]. Therapy with Cetrorelix produced a decrease in bone pain, relief in urinary outflow obstruction, reduction in serum testosterone, and a decrease in PSA levels. The second study involved 36 patients with advanced prostate cancer with elevated PSA and bone pain [<CitationRef CitationID="CR89_2">89</CitationRef>]. Group I consisted of 16 patients, who received 500 µg of Cetrorelix b.i.d. for up to 37 months. Thirteen patients responded but later five patients relapsed [<CitationRef CitationID="CR89_2">89</CitationRef>]. Group II included 20 patients who received a loading dose of Cetrorelix, 5 mg b.i.d. for the first 2 days and thereafter 800 µg b.i.d. for up to 20 months. Nineteen patients showed a clinical remission but later three relapsed. Five of six patients who were paraplegic due to metastatic invasion of spinal cord showed neurologic improvement during therapy with Cetrorelix [<CitationRef CitationID="CR90_2">90</CitationRef>]. Cetrorelix may be indicated for patients with prostate cancer and metastases to the spinal cord, bone marrow, and other sites in whom the LHRH agonists cannot be used as single drugs because of the possibility of flare-up [<CitationRef CitationID="CR6_2">6</CitationRef>, <CitationRef CitationID="CR72_2">72</CitationRef>, <CitationRef CitationID="CR73_2">73</CitationRef>, <CitationRef CitationID="CR90_2">90</CitationRef>].</Para>
              <Para TextBreak="No">Other studies have demonstrated that administration of a depot formulation of the LHRH antagonist abarelix produces a faster reduction in testosterone levels than is achieved with Leuprolide, with or without concomitant antiandrogens [<CitationRef CitationID="CR91_2">91</CitationRef>, <CitationRef CitationID="CR92_2">92</CitationRef>]. Leuprolide and abarelix were equally effective in maintaining serum testosterone at castration levels and in decreasing PSA levels [<CitationRef CitationID="CR91_2">91</CitationRef>, <CitationRef CitationID="CR92_2">92</CitationRef>]. However, some patients treated with abarelix experience allergic reactions. Treatment of patients with androgen-independent prostate cancer with abarelix does not fully suppress serum FSH or lower PSA levels [<CitationRef CitationID="CR93_2">93</CitationRef>]. Thus, LHRH antagonists are of no therapeutic benefits in patients with relapsed prostate cancer [<CitationRef CitationID="CR6_2">6</CitationRef>, <CitationRef CitationID="CR72_2">72</CitationRef>].</Para>
              <Para TextBreak="No">Clinical phase II trials with a new LHRH antagonist, degarelix, in men with prostate cancer indicate that the LHRH receptor blocker administered at initial doses of 200–240 mg and subsequently at monthly maintenance doses of 80–160 mg suppresses serum testosterone levels to ≤0.5 ng/ml [<CitationRef CitationID="CR37a_2">37a</CitationRef>]. A 90% reduction in PSA was achieved in 8 weeks and after 1 year PSA levels were decreased by 97–98%. Degarelix shows a similar efficacy to Leuprolide but it acts much more rapidly. Degarelix’s effectiveness in attaining and maintaining serum testosterone suppression to medical castration levels and with no evidence of testosterone surge during 12 months of treatment in a phase III trial led to its US FDA approval at the end of 2008 for the treatment of patients with advanced prostate cancer [<CitationRef CitationID="CR37b_2">37b</CitationRef>]. Phase I or II studies in men with prostate cancer with other LHRH receptor antagonists, teverelix, acycline, and ozarelix have been also completed. Orally active LHRH antagonists are also being developed [<CitationRef CitationID="CR39_2">39</CitationRef>]. Because of their prompt action LHRH antagonists would be even better suited for intermittent therapy than the agonists; however, in men with prostate cancer, LHRH antagonists have to be given at larger doses than LHRH agonists and thus would entail greater costs.</Para>
              <Para TextBreak="No">In conclusion, it has been documented in thousands of patients with advanced prostate cancer that LHRH agonists provide an effective palliative therapy. LHRH antagonists may also find an application for treatment of prostate cancer. However, all hormonal therapies aimed at androgen deprivation, including castration and LHRH agonists or antagonists, provide only a palliation and disease remission with a limited duration, and most patients with advanced prostatic carcinoma eventually relapse [<CitationRef CitationID="CR6_2">6</CitationRef>, <CitationRef CitationID="CR72_2">72</CitationRef>, <CitationRef CitationID="CR73_2">73</CitationRef>].</Para>
              <Para TextBreak="No">The treatment of relapsed castration-resistant prostate cancer remains a major oncological challenge. One of the approaches for improving the therapeutic response and its duration could be based on combining LHRH agonists or antagonist with other peptides such as GHRH antagonists [<CitationRef CitationID="CR94_2">94</CitationRef>, <CitationRef CitationID="CR95_2">95</CitationRef>] or the use of cytotoxic LHRH analogs [<CitationRef CitationID="CR18_2">18</CitationRef>, <CitationRef CitationID="CR96_2">96</CitationRef>, <CitationRef CitationID="CR97_2">97</CitationRef>].</Para>
            </Section2>
            <Section2 ID="Sec17">
              <Heading>Use of Cytotoxic LHRH Analogs in Prostate Cancer</Heading>
              <Para TextBreak="No">Because most of human prostate cancers exhibited receptors for LHRH [<CitationRef CitationID="CR47_2">47</CitationRef>], targeted cytotoxic analogs were extensively studied in various models of prostate cancer. In rats bearing Dunning R-3327-H or androgen-independent R-3327-AT-1 prostate cancers, significant growth inhibition was observed after administration of AN-207 [<CitationRef CitationID="CR18_2">18</CitationRef>]. In PC-82 human prostate cancers xenografted into nude mice, AN-207 induced a major reduction in tumor volume and a fall in serum PSA levels [<CitationRef CitationID="CR18_2">18</CitationRef>]. Radical AN-201 had only a minor effect and was toxic. Cytotoxic analog AN-207 also inhibited growth of MDA-PCa-2b human prostate cancers [<CitationRef CitationID="CR97_2">97</CitationRef>]. Cytotoxic analog AN-152 also strongly suppressed the growth of androgen-sensitive LNCaP and MDA-PCa-2b prostate cancers and was more effective than doxorubicin [<CitationRef CitationID="CR96_2">96</CitationRef>]. In nude mice with androgen-independent intraosseous C4-2 prostate cancers, AN-152 decreased serum PSA levels but doxorubicin had no effect [<CitationRef CitationID="CR96_2">96</CitationRef>]. Thus, targeted chemotherapy with cytotoxic LHRH analogs should be more efficacious than systemic chemotherapy in patients with relapsed prostate cancers, and clinical trials are pending. Cytotoxic analogs of LHRH might also be indicated for primary therapy of patients with advanced prostate cancer [<CitationRef CitationID="CR6_2">6</CitationRef>, <CitationRef CitationID="CR72_2">72</CitationRef>].</Para>
            </Section2>
            <Section2 ID="Sec18">
              <Heading>Side Effects</Heading>
              <Para TextBreak="No">Cytotoxic LHRH analogs have fewer side effects than do the respective cytotoxic radicals doxorubicin and AN-201. Side effects caused by cytotoxic analogs and the cytotoxic moiety that dissociated from the peptide carrier in the circulation may affect normal cells expressing LHRH receptor. Pituitary cells secreting LH and FSH are the principal nontumoral targets of cytotoxic LHRH analogs. However, the damage to these cells may not be detrimental since patients with hormone-dependent cancers have tolerated treatment by hypophysectomy in the past years [<CitationRef CitationID="CR6_2">6</CitationRef>, <CitationRef CitationID="CR15_2">15</CitationRef>, <CitationRef CitationID="CR16_2">16</CitationRef>, <CitationRef CitationID="CR18_2">18</CitationRef>, <CitationRef CitationID="CR50_2">50</CitationRef>]. Furthermore, our investigations showed that treatment with AN-207 causes only a transient decrease in levels of LHRH receptors or gonadotrophs, and pituitary function recovers after cessation of treatment [<CitationRef CitationID="CR50_2">50</CitationRef>, <CitationRef CitationID="CR78_2">78</CitationRef>, <CitationRef CitationID="CR98_2">98</CitationRef>, <CitationRef CitationID="CR99_2">99</CitationRef>]. These results indicate that the therapy with cytotoxic LHRH analogs will not inflict permanent damage on pituitary functions. The main side effect of cytotoxic LHRH analogs is myelotoxicity [<CitationRef CitationID="CR6_2">6</CitationRef>, <CitationRef CitationID="CR16_2">16</CitationRef>, <CitationRef CitationID="CR18_2">18</CitationRef>]. In clinical phase I studies, women with gynecologic cancers expressing receptors for LHRH were given AN-152 by intravenous infusion in escalating doses up to 267 mg/m<Superscript>2</Superscript>. Leukocytopenia was observed but it was rapidly reversible [<CitationRef CitationID="CR100_2">100</CitationRef>]. Cytotoxic LHRH analog AN-152 is now in clinical phase II trials in women with ovarian and endometrial cancers. Clinical trials with AN-152 in men with relapsed prostate cancers are in a planning stage. A new drug, abiraterone, which can be used orally and which might better control advanced prostatic disease is now in clinical trials in UK.</Para>
            </Section2>
          </Section1>
        </Body>
        <BodyRef FileRef="BodyRef/PDF/978-1-60327-829-4_Chapter_2.pdf" OutputMedium="Online" PDFType="Typeset" TargetType="OnlinePDF"/>
        <ChapterBackmatter>
          <Acknowledgments>
            <Heading>Acknowledgment</Heading>
            <SimplePara>Experimental studies cited in this review were supported by the Medical Research Service of the Veterans Affairs Department.</SimplePara>
          </Acknowledgments>
          <Bibliography ID="Bib1">
            <Heading>References</Heading>
            <Citation ID="CR1_2">
              <CitationNumber>1</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>AV</Initials>
                  <FamilyName>Schally</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Arimura</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>AJ</Initials>
                  <FamilyName>Kastin</FamilyName>
                </BibAuthorName>
                <Year>1971</Year>
                <ArticleTitle Language="En">Hypothalamic FSH and LH-regulating hormone: Structure, physiology and clinical studies</ArticleTitle>
                <JournalTitle>Fertil Steril</JournalTitle>
                <VolumeID>22</VolumeID>
                <FirstPage>703</FirstPage>
                <LastPage>721</LastPage>
                <Occurrence Type="PID">
                  <Handle>4941683</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaE38XjtVOrug%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Schally AV, Arimura A, Kastin AJ. Hypothalamic FSH and LH-regulating hormone: Structure, physiology and clinical studies. Fertil Steril 1971;22:703–721.</BibUnstructured>
            </Citation>
            <Citation ID="CR2_2">
              <CitationNumber>2</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>AV</Initials>
                  <FamilyName>Schally</FamilyName>
                </BibAuthorName>
                <Year>1978</Year>
                <ArticleTitle Language="En">Aspects of hypothalamic regulation of the pituitary gland</ArticleTitle>
                <JournalTitle>Science</JournalTitle>
                <VolumeID>202</VolumeID>
                <FirstPage>18</FirstPage>
                <LastPage>28</LastPage>
                <Occurrence Type="PID">
                  <Handle>99816</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DyaE1M%2FhsVaqsw%3D%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1126/science.99816</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Schally AV. Aspects of hypothalamic regulation of the pituitary gland. Science 1978;202:18–28.</BibUnstructured>
            </Citation>
            <Citation ID="CR3_2">
              <CitationNumber>3</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>RN</Initials>
                  <FamilyName>Clayton</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>KJ</Initials>
                  <FamilyName>Catt</FamilyName>
                </BibAuthorName>
                <Year>1981</Year>
                <ArticleTitle Language="En">GnRH receptors: Characterization, physiologic regulation and relationship to reproductive functions</ArticleTitle>
                <JournalTitle>Endocr Rev</JournalTitle>
                <VolumeID>2</VolumeID>
                <IssueID>2</IssueID>
                <FirstPage>186</FirstPage>
                <LastPage>209</LastPage>
                <Occurrence Type="PID">
                  <Handle>6271547</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaL38XmtlSitw%3D%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1210/edrv-2-2-186</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Clayton RN, Catt KJ. GnRH receptors: Characterization, physiologic regulation and relationship to reproductive functions. Endocr Rev 1981;2(2):186–209.</BibUnstructured>
            </Citation>
            <Citation ID="CR4_2">
              <CitationNumber>4</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>PM</Initials>
                  <FamilyName>Conn</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>WR</Initials>
                  <FamilyName>Huckle</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>WV</Initials>
                  <FamilyName>Anders</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>CA</Initials>
                  <FamilyName>McArdle</FamilyName>
                </BibAuthorName>
                <Year>1987</Year>
                <ArticleTitle Language="En">The molecular mechanism of action of gonadotropin releasing hormone (GnRH) in the pituitary</ArticleTitle>
                <JournalTitle>Recent Prog Horm Res</JournalTitle>
                <VolumeID>43</VolumeID>
                <FirstPage>29</FirstPage>
                <LastPage>68</LastPage>
                <Occurrence Type="PID">
                  <Handle>2819996</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaL2sXmt12hsLc%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Conn PM, Huckle WR, Anders WV, McArdle CA. The molecular mechanism of action of gonadotropin releasing hormone (GnRH) in the pituitary. Recent Prog Horm Res 1987;43:29–68.</BibUnstructured>
            </Citation>
            <Citation ID="CR5_2">
              <CitationNumber>5</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>RP</Initials>
                  <FamilyName>Millar</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>ZL</Initials>
                  <FamilyName>Lu</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>AJ</Initials>
                  <FamilyName>Pawson</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>CA</Initials>
                  <FamilyName>Flanagan</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>K</Initials>
                  <FamilyName>Morgan</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>SR</Initials>
                  <FamilyName>Maudsley</FamilyName>
                </BibAuthorName>
                <Year>2004</Year>
                <ArticleTitle Language="En">Gonadotropin-releasing hormone receptors</ArticleTitle>
                <JournalTitle>Endocr Rev</JournalTitle>
                <VolumeID>25</VolumeID>
                <FirstPage>235</FirstPage>
                <LastPage>275</LastPage>
                <Occurrence Type="PID">
                  <Handle>15082521</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2cXktFSqtLk%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1210/er.2003-0002</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Millar RP, Lu ZL, Pawson AJ, Flanagan CA, Morgan K, Maudsley SR. Gonadotropin-releasing hormone receptors. Endocr Rev 2004;25;235–275.</BibUnstructured>
            </Citation>
            <Citation ID="CR6_2">
              <CitationNumber>6</CitationNumber>
              <BibChapter>
                <BibAuthorName>
                  <Initials>AV</Initials>
                  <FamilyName>Schally</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>AM</Initials>
                  <FamilyName>Comaru-Schally</FamilyName>
                </BibAuthorName>
                <Year>2006</Year>
                <ChapterTitle Language="En">Hypothalamic and other peptide hormones</ChapterTitle>
                <BibEditorName>
                  <Initials>JF</Initials>
                  <FamilyName>Holland</FamilyName>
                </BibEditorName>
                <BibEditorName>
                  <Initials>E</Initials>
                  <FamilyName>Frei</FamilyName>
                </BibEditorName>
                <BibEditorName>
                  <Initials>RC</Initials>
                  <FamilyName>Bast</FamilyName>
                </BibEditorName>
                <BibEditorName>
                  <Initials>DE</Initials>
                  <FamilyName>Kufe</FamilyName>
                </BibEditorName>
                <BibEditorName>
                  <Initials>RE</Initials>
                  <FamilyName>Pollock</FamilyName>
                </BibEditorName>
                <BibEditorName>
                  <Initials>RR</Initials>
                  <FamilyName>Weichselbaum</FamilyName>
                </BibEditorName>
                <BibEditorName>
                  <Initials>WN</Initials>
                  <FamilyName>Hait</FamilyName>
                </BibEditorName>
                <BibEditorName>
                  <Initials>WK</Initials>
                  <FamilyName>Hong</FamilyName>
                </BibEditorName>
                <Eds/>
                <BookTitle>Cancer medicine</BookTitle>
                <EditionNumber>7</EditionNumber>
                <PublisherName>BC Dekker</PublisherName>
                <PublisherLocation>Hamilton, ON</PublisherLocation>
                <FirstPage>802</FirstPage>
                <LastPage>816</LastPage>
              </BibChapter>
              <BibUnstructured>Schally AV, Comaru-Schally AM. Hypothalamic and other peptide hormones. In: Holland JF, Frei E, Bast RC, Kufe DE, Pollock RE, Weichselbaum RR, Hait WN, Hong WK, eds. Cancer medicine. 7th ed. Hamilton, ON: BC Dekker, 2006:802–816.</BibUnstructured>
            </Citation>
            <Citation ID="CR7_2">
              <CitationNumber>7</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>AV</Initials>
                  <FamilyName>Schally</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>AV</Initials>
                  <FamilyName>Comaru-Schally</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Nagy</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2001</Year>
                <ArticleTitle Language="En">Hypothalamic hormones and cancer</ArticleTitle>
                <JournalTitle>Front Neuroendocrinol</JournalTitle>
                <VolumeID>22</VolumeID>
                <FirstPage>248</FirstPage>
                <LastPage>291</LastPage>
                <Occurrence Type="PID">
                  <Handle>11587553</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3MXnt1OktLw%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1006/frne.2001.0217</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Schally AV, Comaru-Schally AV, Nagy A, et al. Hypothalamic hormones and cancer. Front Neuroendocrinol 2001;22:248–291.</BibUnstructured>
            </Citation>
            <Citation ID="CR8_2">
              <CitationNumber>8</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>T</Initials>
                  <FamilyName>Reissmann</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>AV</Initials>
                  <FamilyName>Schally</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>P</Initials>
                  <FamilyName>Bouchard</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>H</Initials>
                  <FamilyName>Riethmuller</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Engel</FamilyName>
                </BibAuthorName>
                <Year>2000</Year>
                <ArticleTitle Language="En">The LHRH antagonist cetrorelix: A review</ArticleTitle>
                <JournalTitle>Hum Reprod Update</JournalTitle>
                <VolumeID>6</VolumeID>
                <FirstPage>322</FirstPage>
                <LastPage>331</LastPage>
                <Occurrence Type="PID">
                  <Handle>10972520</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3cXmslWgtLc%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1093/humupd/6.4.322</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Reissmann T, Schally AV, Bouchard P, Riethmuller H, Engel J. The LHRH antagonist cetrorelix: A review. Hum Reprod Update 2000;6:322–331.</BibUnstructured>
            </Citation>
            <Citation ID="CR9_2">
              <CitationNumber>9</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>G</Initials>
                  <FamilyName>Griesinger</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>R</Initials>
                  <FamilyName>Felberbaum</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>K</Initials>
                  <FamilyName>Diedrich</FamilyName>
                </BibAuthorName>
                <Year>2005</Year>
                <ArticleTitle Language="En">GnRH-antagonists in reproductive medicine</ArticleTitle>
                <JournalTitle>Arch Gynecol Obstet</JournalTitle>
                <VolumeID>273</VolumeID>
                <FirstPage>71</FirstPage>
                <LastPage>78</LastPage>
                <Occurrence Type="PID">
                  <Handle>15991015</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2MXhtlWktrbP</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1007/s00404-005-0021-2</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Griesinger G, Felberbaum R, Diedrich K. GnRH-antagonists in reproductive medicine. Arch Gynecol Obstet 2005;273:71–78.</BibUnstructured>
            </Citation>
            <Citation ID="CR10_2">
              <CitationNumber>10</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Kovács</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>AV</Initials>
                  <FamilyName>Schally</FamilyName>
                </BibAuthorName>
                <Year>2001</Year>
                <ArticleTitle Language="En">Comparison of mechanism of action of LHRH antagonist cetrorelix and LHRH agonist triptorelin on the gne expression of pituitary LHRH receptors in rats</ArticleTitle>
                <JournalTitle>Proc Natl Acad Sci USA</JournalTitle>
                <VolumeID>987</VolumeID>
                <FirstPage>12197</FirstPage>
                <LastPage>12202</LastPage>
                <Occurrence Type="DOI">
                  <Handle>10.1073/pnas.211442598</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Kovács M, Schally AV. Comparison of mechanism of action of LHRH antagonist cetrorelix and LHRH agonist triptorelin on the gne expression of pituitary LHRH receptors in rats. Proc Natl Acad Sci USA 2001;987:12197–12202.</BibUnstructured>
            </Citation>
            <Citation ID="CR11_2">
              <CitationNumber>11</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Kovács</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>AV</Initials>
                  <FamilyName>Schally</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>B</Initials>
                  <FamilyName>Csernus</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>Z</Initials>
                  <FamilyName>Rekasi</FamilyName>
                </BibAuthorName>
                <Year>2001</Year>
                <ArticleTitle Language="En">LHRH antagonist cetrorelix downregulates the mRNA expression of pituitary receptors for LHRH by counteracting the stimulatory effect of endogenous LHRH</ArticleTitle>
                <JournalTitle>Proc Natl Aca Sci USA</JournalTitle>
                <VolumeID>98</VolumeID>
                <FirstPage>1829</FirstPage>
                <LastPage>1834</LastPage>
                <Occurrence Type="DOI">
                  <Handle>10.1073/pnas.98.4.1829</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Kovács M, Schally AV, Csernus B, Rekasi Z. LHRH antagonist cetrorelix downregulates the mRNA expression of pituitary receptors for LHRH by counteracting the stimulatory effect of endogenous LHRH. Proc Natl Aca Sci USA 2001;98:1829–1834.</BibUnstructured>
            </Citation>
            <Citation ID="CR12_2">
              <CitationNumber>12</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>JE</Initials>
                  <FamilyName>Horvath</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>AM</Initials>
                  <FamilyName>Bajo</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>AV</Initials>
                  <FamilyName>Schally</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Kovács</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>F</Initials>
                  <FamilyName>Herbert</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>K</Initials>
                  <FamilyName>Groot</FamilyName>
                </BibAuthorName>
                <Year>2002</Year>
                <ArticleTitle Language="En">Effects of long-term treatment with the luteinizing hormone-releasing hormone (LHRH) agonist Decapeptyl and the LHRH antagonist Cetrorelix on the level of pituitary LHRH receptors and their mRNA expression in rats</ArticleTitle>
                <JournalTitle>Proc Natl Acad Sci USA</JournalTitle>
                <VolumeID>99</VolumeID>
                <FirstPage>15048</FirstPage>
                <LastPage>15053</LastPage>
                <Occurrence Type="PID">
                  <Handle>12409615</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD38Xpt1yrurk%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1073/pnas.232579499</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Horvath JE, Bajo AM, Schally AV, Kovács M, Herbert F, Groot K. Effects of long-term treatment with the luteinizing hormone-releasing hormone (LHRH) agonist Decapeptyl and the LHRH antagonist Cetrorelix on the level of pituitary LHRH receptors and their mRNA expression in rats. Proc Natl Acad Sci U S A 2002;99:15048–15053.</BibUnstructured>
            </Citation>
            <Citation ID="CR13_2">
              <CitationNumber>13</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>AV</Initials>
                  <FamilyName>Schally</FamilyName>
                </BibAuthorName>
                <Year>1999</Year>
                <ArticleTitle Language="En">Luteinizing hormone releasing-hormone analogues: Their impact on the control of tumorigenesis</ArticleTitle>
                <JournalTitle>Peptides</JournalTitle>
                <VolumeID>20</VolumeID>
                <FirstPage>1247</FirstPage>
                <LastPage>1262</LastPage>
                <Occurrence Type="PID">
                  <Handle>10573298</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK1MXntVCnsrc%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/S0196-9781(99)00130-8</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Schally AV. Luteinizing hormone releasing-hormone analogues: Their impact on the control of tumorigenesis. Peptides 1999;20:1247–1262.</BibUnstructured>
            </Citation>
            <Citation ID="CR14_2">
              <CitationNumber>14</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Maudsley</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>L</Initials>
                  <FamilyName>Davidson</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>AJ</Initials>
                  <FamilyName>Pawson</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>R</Initials>
                  <FamilyName>Chan</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>R</Initials>
                  <FamilyName>Lopez de Maturana</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>RP</Initials>
                  <FamilyName>Millar</FamilyName>
                </BibAuthorName>
                <Year>2004</Year>
                <ArticleTitle Language="En">Gonadotropin-releasing hormone (GnRH) antagonists promote proapoptotic signaling in peripheral reproductive tumor cells by activating a Galphai-coupling state of the type I GnRH receptor</ArticleTitle>
                <JournalTitle>Cancer Res</JournalTitle>
                <VolumeID>64</VolumeID>
                <FirstPage>7533</FirstPage>
                <LastPage>7544</LastPage>
                <Occurrence Type="PID">
                  <Handle>15492280</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2cXosFynu78%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1158/0008-5472.CAN-04-1360</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Maudsley S, Davidson L, Pawson AJ, Chan R, Lopez de Maturana R, Millar RP. Gonadotropin-releasing hormone (GnRH) antagonists promote proapoptotic signaling in peripheral reproductive tumor cells by activating a Galphai-coupling state of the type I GnRH receptor. Cancer Res 2004;64:7533–7544.</BibUnstructured>
            </Citation>
            <Citation ID="CR15_2">
              <CitationNumber>15</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>AV</Initials>
                  <FamilyName>Schally</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Nagy</FamilyName>
                </BibAuthorName>
                <Year>1999</Year>
                <ArticleTitle Language="En">Cancer chemotherapy based on targeting of cytotoxic peptide conjugates to their receptors on tumors</ArticleTitle>
                <JournalTitle>Eur J Endocrinol</JournalTitle>
                <VolumeID>141</VolumeID>
                <FirstPage>1</FirstPage>
                <LastPage>14</LastPage>
                <Occurrence Type="PID">
                  <Handle>10407215</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK1MXltVeru78%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1530/eje.0.1410001</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Schally AV, Nagy A. Cancer chemotherapy based on targeting of cytotoxic peptide conjugates to their receptors on tumors. Eur J Endocrinol 1999;141:1–14.</BibUnstructured>
            </Citation>
            <Citation ID="CR16_2">
              <CitationNumber>16</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>AV</Initials>
                  <FamilyName>Schally</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Nagy</FamilyName>
                </BibAuthorName>
                <Year>2003</Year>
                <ArticleTitle Language="En">New approaches to treatment of various cancers based on cytotoxic analogs of LHRH, somatostatin and bombesin</ArticleTitle>
                <JournalTitle>Life Sci</JournalTitle>
                <VolumeID>72</VolumeID>
                <FirstPage>2305</FirstPage>
                <LastPage>2320</LastPage>
                <Occurrence Type="PID">
                  <Handle>12639697</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3sXhvFajsbo%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/S0024-3205(03)00113-9</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Schally AV, Nagy A. New approaches to treatment of various cancers based on cytotoxic analogs of LHRH, somatostatin and bombesin. Life Sci 2003;72:2305–2320.</BibUnstructured>
            </Citation>
            <Citation ID="CR17_2">
              <CitationNumber>17</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>JL</Initials>
                  <FamilyName>Krebs</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>X</Initials>
                  <FamilyName>Wang</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>HE</Initials>
                  <FamilyName>Pudavar</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2000</Year>
                <ArticleTitle Language="En">Regulation of targeted chemotherapy with cytotoxic LHRH analog by epidermal growth factor</ArticleTitle>
                <JournalTitle>Cancer Res</JournalTitle>
                <VolumeID>60</VolumeID>
                <FirstPage>4194</FirstPage>
                <LastPage>4199</LastPage>
                <Occurrence Type="PID">
                  <Handle>10945629</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3cXlvFOktL8%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Krebs JL, Wang X, Pudavar HE, et al. Regulation of targeted chemotherapy with cytotoxic LHRH analog by epidermal growth factor. Cancer Res 2000;60:4194–4199.</BibUnstructured>
            </Citation>
            <Citation ID="CR18_2">
              <CitationNumber>18</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>AV</Initials>
                  <FamilyName>Schally</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Nagy</FamilyName>
                </BibAuthorName>
                <Year>2004</Year>
                <ArticleTitle Language="En">Chemotherapy targeted to cancers through tumoral hormone receptors</ArticleTitle>
                <JournalTitle>Trends Endocrinol Metab</JournalTitle>
                <VolumeID>15</VolumeID>
                <FirstPage>300</FirstPage>
                <LastPage>310</LastPage>
                <Occurrence Type="PID">
                  <Handle>15350601</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2cXntlSgsLg%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/j.tem.2004.07.002</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Schally AV, Nagy A. Chemotherapy targeted to cancers through tumoral hormone receptors. Trends Endocrinol Metab 2004;15:300–310.</BibUnstructured>
            </Citation>
            <Citation ID="CR19_2">
              <CitationNumber>19</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>AV</Initials>
                  <FamilyName>Schally</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Arimura</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>Y</Initials>
                  <FamilyName>Baba</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1971</Year>
                <ArticleTitle Language="En">Isolation and properties of the FSH- and LH-releasing hormone</ArticleTitle>
                <JournalTitle>Biochem Biophys Res Commun</JournalTitle>
                <VolumeID>43</VolumeID>
                <FirstPage>393</FirstPage>
                <LastPage>399</LastPage>
                <Occurrence Type="PID">
                  <Handle>4930860</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaE3MXktVSktLk%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/0006-291X(71)90766-2</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Schally AV, Arimura A, Baba Y, et al. Isolation and properties of the FSH- and LH-releasing hormone. Biochem Biophys Res Commun 1971;43:393–399.</BibUnstructured>
            </Citation>
            <Citation ID="CR20_2">
              <CitationNumber>20</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>H</Initials>
                  <FamilyName>Matsuo</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>Y</Initials>
                  <FamilyName>Baba</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>RMG</Initials>
                  <FamilyName>Nair</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Arimura</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>AV</Initials>
                  <FamilyName>Schally</FamilyName>
                </BibAuthorName>
                <Year>1971</Year>
                <ArticleTitle Language="En">Structure of the porcine LH- and FSH-releasing hormone. I. The proposed amino acid sequence</ArticleTitle>
                <JournalTitle>Biochem Biophys Res Commun</JournalTitle>
                <VolumeID>43</VolumeID>
                <FirstPage>1334</FirstPage>
                <LastPage>1339</LastPage>
                <Occurrence Type="PID">
                  <Handle>4936338</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaE3MXksVGiurY%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/S0006-291X(71)80019-0</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Matsuo H, Baba Y, Nair RMG, Arimura A, Schally AV. Structure of the porcine LH- and FSH-releasing hormone. I. The proposed amino acid sequence. Biochem Biophys Res Commun 1971;43:1334–1339.</BibUnstructured>
            </Citation>
            <Citation ID="CR21_2">
              <CitationNumber>21</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>AV</Initials>
                  <FamilyName>Schally</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Arimura</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Kastin</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1971</Year>
                <ArticleTitle Language="En">The gonadotropin-releasing hormone: One polypeptide regulates secretion of luteinizing and follicle-stimulating hormones</ArticleTitle>
                <JournalTitle>Science</JournalTitle>
                <VolumeID>173</VolumeID>
                <FirstPage>1036</FirstPage>
                <LastPage>1038</LastPage>
                <Occurrence Type="PID">
                  <Handle>4938639</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaE38Xkt1Wnug%3D%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1126/science.173.4001.1036</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Schally AV, Arimura A, Kastin A, et al. The gonadotropin-releasing hormone: One polypeptide regulates secretion of luteinizing and follicle-stimulating hormones. Science 1971;173:1036–1038.</BibUnstructured>
            </Citation>
            <Citation ID="CR22_2">
              <CitationNumber>22</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>AJ</Initials>
                  <FamilyName>Kastin</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>AV</Initials>
                  <FamilyName>Schally</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>C</Initials>
                  <FamilyName>Gual</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>AR</Initials>
                  <FamilyName>Midgley</FamilyName>
                  <Suffix>Jr</Suffix>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>CY</Initials>
                  <FamilyName>Bowers</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>E</Initials>
                  <FamilyName>Gomez-Perez</FamilyName>
                </BibAuthorName>
                <Year>1970</Year>
                <ArticleTitle Language="En">Administration of LH-releasing hormone to selected human subjects</ArticleTitle>
                <JournalTitle>Am J Obstet Gynecol</JournalTitle>
                <VolumeID>108</VolumeID>
                <FirstPage>177</FirstPage>
                <LastPage>182</LastPage>
                <Occurrence Type="PID">
                  <Handle>4952919</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaE3cXltFKru74%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Kastin AJ, Schally AV, Gual C, Midgley AR Jr, Bowers CY, Gomez-Perez E. Administration of LH-releasing hormone to selected human subjects. Am J Obstet Gynecol 1970;108: 177–182.</BibUnstructured>
            </Citation>
            <Citation ID="CR23_2">
              <CitationNumber>23</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>MJ</Initials>
                  <FamilyName>Karten</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JE</Initials>
                  <FamilyName>Rivier</FamilyName>
                </BibAuthorName>
                <Year>1986</Year>
                <ArticleTitle Language="En">Gonadotropin-releasing hormone analog design. Structure-function studies toward the development of agonists and antagonists: Rationale and perspective</ArticleTitle>
                <JournalTitle>Endocr Rev</JournalTitle>
                <VolumeID>7</VolumeID>
                <FirstPage>44</FirstPage>
                <LastPage>66</LastPage>
                <Occurrence Type="PID">
                  <Handle>2420580</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaL28XitVShtr8%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1210/edrv-7-1-44</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Karten MJ, Rivier JE. Gonadotropin-releasing hormone analog design. Structure-function studies toward the development of agonists and antagonists: Rationale and perspective. Endocr Rev 1986;7:44–66.</BibUnstructured>
            </Citation>
            <Citation ID="CR24_2">
              <CitationNumber>24</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>AV</Initials>
                  <FamilyName>Schally</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>AJ</Initials>
                  <FamilyName>Kastin</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DH</Initials>
                  <FamilyName>Coy</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>T</Initials>
                  <FamilyName>Edward</FamilyName>
                </BibAuthorName>
                <Year>1976</Year>
                <ArticleTitle Language="En">Tyler Prize Oration. LH-releasing hormone and its analogs: Recent basic and clinical investigations</ArticleTitle>
                <JournalTitle>Int J Fertil</JournalTitle>
                <VolumeID>21</VolumeID>
                <FirstPage>1</FirstPage>
                <LastPage>30</LastPage>
                <Occurrence Type="PID">
                  <Handle>8392</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaE28XksFOjs78%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Schally AV, Kastin AJ, Coy DH, Edward T. Tyler Prize Oration. LH-releasing hormone and its analogs: recent basic and clinical investigations. Int J Fertil 1976;21:1–30.</BibUnstructured>
            </Citation>
            <Citation ID="CR25_2">
              <CitationNumber>25</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>DH</Initials>
                  <FamilyName>Coy</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JA</Initials>
                  <FamilyName>Vilchez-Martinez</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>EJ</Initials>
                  <FamilyName>Coy</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>AV</Initials>
                  <FamilyName>Schally</FamilyName>
                </BibAuthorName>
                <Year>1976</Year>
                <ArticleTitle Language="En">Analogs of luteinizing hormone-releasing hormone with increased biological activity produced by D-amino acid substitutions in position 6</ArticleTitle>
                <JournalTitle>J Med Chem</JournalTitle>
                <VolumeID>19</VolumeID>
                <FirstPage>423</FirstPage>
                <LastPage>425</LastPage>
                <Occurrence Type="PID">
                  <Handle>1255667</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaE28XpvFOhsQ%3D%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1021/jm00225a018</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Coy DH, Vilchez-Martinez JA, Coy EJ, Schally AV. Analogs of luteinizing hormone-releasing hormone with increased biological activity produced by D-amino acid substitutions in position 6. J Med Chem 1976;19:423–425.</BibUnstructured>
            </Citation>
            <Citation ID="CR26_2">
              <CitationNumber>26</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Fujino</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>T</Initials>
                  <FamilyName>Fukuda</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Shinagawa</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1974</Year>
                <ArticleTitle Language="En">Synthetic analogs of luteinizing hormone-releasing hormone (LHRH) substituted in positions 6 and 10</ArticleTitle>
                <JournalTitle>Biochem Biophys Res Commun</JournalTitle>
                <VolumeID>57</VolumeID>
                <FirstPage>1248</FirstPage>
                <LastPage>1256</LastPage>
                <Occurrence Type="PID">
                  <Handle>4598337</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DyaE2c7ntFakuw%3D%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/0006-291X(74)90830-4</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Fujino M, Fukuda T, Shinagawa S, et al. Synthetic analogs of luteinizing hormone-releasing hormone (LHRH) substituted in positions 6 and 10. Biochem Biophys Res Commun 1974;57:1248–1256.</BibUnstructured>
            </Citation>
            <Citation ID="CR27_2">
              <CitationNumber>27</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>AN</Initials>
                  <FamilyName>Dutta</FamilyName>
                </BibAuthorName>
                <Year>1988</Year>
                <ArticleTitle Language="En">Luteinizing hormone-releasing hormone (LHRH) agonists</ArticleTitle>
                <JournalTitle>Drugs Future</JournalTitle>
                <VolumeID>13</VolumeID>
                <FirstPage>43</FirstPage>
                <LastPage>57</LastPage>
              </BibArticle>
              <BibUnstructured>Dutta AN. Luteinizing hormone-releasing hormone (LHRH) agonists. Drugs Future 1988;13:43–57.</BibUnstructured>
            </Citation>
            <Citation ID="CR28_2">
              <CitationNumber>28</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>SS</Initials>
                  <FamilyName>Kakar</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>WE</Initials>
                  <FamilyName>Grizzle</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JD</Initials>
                  <FamilyName>Neill</FamilyName>
                </BibAuthorName>
                <Year>1994</Year>
                <ArticleTitle Language="En">The nucleotide sequences of human GnRH receptors in breast and ovarian tumors are identical in that found in pituitary</ArticleTitle>
                <JournalTitle>Mol Cell Endocrinol</JournalTitle>
                <VolumeID>106</VolumeID>
                <FirstPage>145</FirstPage>
                <LastPage>149</LastPage>
                <Occurrence Type="PID">
                  <Handle>7534732</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK2MXitlaksrk%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/0303-7207(94)90196-1</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Kakar SS, Grizzle WE, Neill JD. The nucleotide sequences of human GnRH receptors in breast and ovarian tumors are identical in that found in pituitary. Mol Cell Endocrinol 1994;106:145–149.</BibUnstructured>
            </Citation>
            <Citation ID="CR29_2">
              <CitationNumber>29</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>JD</Initials>
                  <FamilyName>Neill</FamilyName>
                </BibAuthorName>
                <Year>2002</Year>
                <ArticleTitle Language="En">GnRH and GnRH receptor genes in the human genome</ArticleTitle>
                <JournalTitle>Endocrinology</JournalTitle>
                <VolumeID>143</VolumeID>
                <FirstPage>737</FirstPage>
                <LastPage>743</LastPage>
                <Occurrence Type="PID">
                  <Handle>11861490</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD38XhvVejtbc%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1210/en.143.3.737</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Neill JD. GnRH and GnRH receptor genes in the human genome. Endocrinology 2002;143:737–743.</BibUnstructured>
            </Citation>
            <Citation ID="CR30_2">
              <CitationNumber>30</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>PN</Initials>
                  <FamilyName>Schlegel</FamilyName>
                </BibAuthorName>
                <Year>2006</Year>
                <ArticleTitle Language="En">Efficacy and safety of histrelin subdermal implant in patients with advanced prostate cancer</ArticleTitle>
                <JournalTitle>J Urol</JournalTitle>
                <VolumeID>175</VolumeID>
                <FirstPage>1353</FirstPage>
                <LastPage>1358</LastPage>
                <Occurrence Type="PID">
                  <Handle>16515997</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD28XjtlWkurk%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/S0022-5347(05)00649-X</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Schlegel PN. Efficacy and safety of histrelin subdermal implant in patients with advanced prostate cancer. J Urol 2006;175:1353–1358.</BibUnstructured>
            </Citation>
            <Citation ID="CR31_2">
              <CitationNumber>31</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Bajusz</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Kovács</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Gazdag</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1988</Year>
                <ArticleTitle Language="En">Highly potent antagonists of luteinizing hormone-releasing hormone free of edematogenic effects</ArticleTitle>
                <JournalTitle>Proc Natl Acad Sci USA</JournalTitle>
                <VolumeID>85</VolumeID>
                <FirstPage>1637</FirstPage>
                <LastPage>1641</LastPage>
                <Occurrence Type="PID">
                  <Handle>3278323</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaL1cXhvVShtbw%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1073/pnas.85.5.1637</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Bajusz S, Kovács M, Gazdag M, eta al. Highly potent antagonists of luteinizing hormone-releasing hormone free of edematogenic effects. Proc Natl Acad Sci USA 1988;85:1637–1641.</BibUnstructured>
            </Citation>
            <Citation ID="CR32_2">
              <CitationNumber>32</CitationNumber>
              <BibChapter>
                <BibAuthorName>
                  <Initials>AV</Initials>
                  <FamilyName>Schally</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Engel</FamilyName>
                </BibAuthorName>
                <Year>2006</Year>
                <ChapterTitle Language="En">Analogs of luteinizing hormone-releasing hormone (LHRH) in cancer</ChapterTitle>
                <BibEditorName>
                  <Initials>AJ</Initials>
                  <FamilyName>Kastin</FamilyName>
                </BibEditorName>
                <Eds/>
                <BookTitle>Handbook of biologically active peptides</BookTitle>
                <PublisherName>Academic Press</PublisherName>
                <PublisherLocation>New York</PublisherLocation>
                <FirstPage>421</FirstPage>
                <LastPage>427</LastPage>
                <Occurrence Type="DOI">
                  <Handle>10.1016/B978-012369442-3/50063-5</Handle>
                </Occurrence>
              </BibChapter>
              <BibUnstructured>Schally AV, Engel J. Analogs of luteinizing hormone-releasing hormone (LHRH) in cancer. In: Handbook of biologically active peptides. Kastin AJ, ed. Academic Press: New York, 2006:421–427.</BibUnstructured>
            </Citation>
            <Citation ID="CR33_2">
              <CitationNumber>33</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>LR</Initials>
                  <FamilyName>Nelson</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>VY</Initials>
                  <FamilyName>Fujimoto</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>RB</Initials>
                  <FamilyName>Jaffe</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>SE</Initials>
                  <FamilyName>Monroe</FamilyName>
                </BibAuthorName>
                <Year>1995</Year>
                <ArticleTitle Language="En">Suppression of follicular phase pituitary gonadal function by a potent new gonadotropin-releasing hormone antagonist with reduced histamine-releasing properties (ganirelix)</ArticleTitle>
                <JournalTitle>Fertil Steril</JournalTitle>
                <VolumeID>63</VolumeID>
                <FirstPage>963</FirstPage>
                <LastPage>969</LastPage>
                <Occurrence Type="PID">
                  <Handle>7536693</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DyaK2M3jslCmsA%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Nelson LR, Fujimoto VY, Jaffe RB, Monroe SE. Suppression of follicular phase pituitary gonadal function by a potent new gonadotropin-releasing hormone antagonist with reduced histamine-releasing properties (ganirelix). Fertil Steril 1995;63:963–969.</BibUnstructured>
            </Citation>
            <Citation ID="CR34_2">
              <CitationNumber>34</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>CJ</Initials>
                  <FamilyName>Molineaux</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>PM</Initials>
                  <FamilyName>Sluss</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MP</Initials>
                  <FamilyName>Bree</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>ML</Initials>
                  <FamilyName>Geefter</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>LM</Initials>
                  <FamilyName>Sullivan</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>BM</Initials>
                  <FamilyName>Garnick</FamilyName>
                </BibAuthorName>
                <Year>1998</Year>
                <ArticleTitle Language="En">Suppression of plasma gonadotropins by Abarelix: A potent new LHRH antagonist</ArticleTitle>
                <JournalTitle>Mol Urol</JournalTitle>
                <VolumeID>2</VolumeID>
                <FirstPage>265</FirstPage>
                <LastPage>268</LastPage>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK1cXnsVCjsr0%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Molineaux CJ, Sluss PM, Bree MP, Geefter ML, Sullivan LM, Garnick BM. Suppression of plasma gonadotropins by Abarelix: A potent new LHRH antagonist. Mol Urol 1998;2:265–268.</BibUnstructured>
            </Citation>
            <Citation ID="CR35_2">
              <CitationNumber>35</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Pinski</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>T</Initials>
                  <FamilyName>Yano</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>K</Initials>
                  <FamilyName>Szepesházi</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>K</Initials>
                  <FamilyName>Groot</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>AV</Initials>
                  <FamilyName>Schally</FamilyName>
                </BibAuthorName>
                <Year>1993</Year>
                <ArticleTitle Language="En">Recovery of pituitary-gonadal function in male rats after long-term suppression induced by a single injection of microcapsules of LH-RH antagonist cetrorelix SB-75</ArticleTitle>
                <JournalTitle>J Androl</JournalTitle>
                <VolumeID>14</VolumeID>
                <FirstPage>164</FirstPage>
                <LastPage>169</LastPage>
                <Occurrence Type="PID">
                  <Handle>8407570</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK2cXps1eltg%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Pinski J, Yano T, Szepesházi K, Groot K, Schally AV. Recovery of pituitary-gonadal function in male rats after long-term suppression induced by a single injection of microcapsules of LH-RH antagonist cetrorelix SB-75. J Androl 1993;14:164–169.</BibUnstructured>
            </Citation>
            <Citation ID="CR36_2">
              <CitationNumber>36</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>MP</Initials>
                  <FamilyName>Samant</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DJ</Initials>
                  <FamilyName>Hong</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>G</Initials>
                  <FamilyName>Croston</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>C</Initials>
                  <FamilyName>Rivier</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Rivier</FamilyName>
                </BibAuthorName>
                <Year>2006</Year>
                <ArticleTitle Language="En">Novel analogues of degarelix incorporating hydroxyl-, methoxy- and pegylated-urea moieties at positions 3, 5, 6 and the N-Terminus</ArticleTitle>
                <JournalTitle>J Med Chem</JournalTitle>
                <VolumeID>49</VolumeID>
                <FirstPage>3536</FirstPage>
                <LastPage>3543</LastPage>
                <Occurrence Type="PID">
                  <Handle>16759096</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD28XkvVeht74%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1021/jm060240a</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Samant MP, Hong DJ, Croston G, Rivier C, Rivier J. Novel analogues of degarelix incorporating hydroxyl-, methoxy- and pegylated-urea moieties at positions 3,5,6 and the N-Terminus. J Med Chem 2006;49:3536–3543.</BibUnstructured>
            </Citation>
            <Citation ID="CR37_2">
              <CitationNumber>37</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>H</Initials>
                  <FamilyName>Poppel</FamilyName>
                  <Particle>Van</Particle>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>B</Initials>
                  <FamilyName>Tombal</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JJ</Initials>
                  <FamilyName>Rosette</FamilyName>
                  <Particle>de la</Particle>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>BE</Initials>
                  <FamilyName>Persson</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JK</Initials>
                  <FamilyName>Jensen</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>OT</Initials>
                  <FamilyName>Kold</FamilyName>
                </BibAuthorName>
                <Year>2008</Year>
                <ArticleTitle Language="En">Degarelix: a novel gonadotropin-releasing hormone (GNRH) receptor blocker-results from a 1-yr, multicentre, randomized, phase 2 dosage-finding study in the treatment of prostate cancer</ArticleTitle>
                <JournalTitle>Eur Urol</JournalTitle>
                <VolumeID>54</VolumeID>
                <FirstPage>805</FirstPage>
                <LastPage>813</LastPage>
                <Occurrence Type="PID">
                  <Handle>18538469</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/j.eururo.2008.04.065</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD1cXhtlGgu7%2FN</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Van Poppel H, Tombal B, de la Rosette JJ, Persson BE, Jensen JK, Kold OT. Degarelix: a novel gonadotropin-releasing hormone (GNRH) receptor blocker-results from a 1-yr, multicentre, randomized, phase 2 dosage-finding study in the treatment of prostate cancer. Eur Urol 2008;54:805–813.</BibUnstructured>
            </Citation>
            <Citation ID="CR37a_2">
              <CitationNumber>37a</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>G</Initials>
                  <FamilyName>Emons</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Kauffmann</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>AR</Initials>
                  <FamilyName>Gunthert</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2007</Year>
                <ArticleTitle Language="En">Phase I study of Zen-008 (AN-152), a targeted cytotoxic LHRH analog in female patients with cancers expressing LHRH receptors</ArticleTitle>
                <JournalTitle>J Clin Oncol</JournalTitle>
                <VolumeID>25</VolumeID>
                <IssueID>18S</IssueID>
                <FirstPage>3571</FirstPage>
                <BibComments>ASCO Annual Meeting Proceedings</BibComments>
              </BibArticle>
              <BibUnstructured>Gittelman M, Pommerville PJ, Persson BE, et al. A 1-year, open label, randomized phase II dose finding study of degarelix for the treatment of prostate cancer in North America. J Urol 2008;180(5):1986–1992.</BibUnstructured>
            </Citation>
            <Citation ID="CR37b_2">
              <CitationNumber>37b</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>G</Initials>
                  <FamilyName>Emons</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Kauffmann</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>AR</Initials>
                  <FamilyName>Gunthert</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2007</Year>
                <ArticleTitle Language="En">Phase I study of Zen-008 (AN-152), a targeted cytotoxic LHRH analog in female patients with cancers expressing LHRH receptors</ArticleTitle>
                <JournalTitle>J Clin Oncol</JournalTitle>
                <VolumeID>25</VolumeID>
                <IssueID>18S</IssueID>
                <FirstPage>3571</FirstPage>
                <BibComments>ASCO Annual Meeting Proceedings</BibComments>
              </BibArticle>
              <BibUnstructured>Klotz L, Boccon-Gibod L, Shore ND, et al. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. BJU Int 2008;102(11):1531–1538.</BibUnstructured>
            </Citation>
            <Citation ID="CR38_2">
              <CitationNumber>38</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>BC</Initials>
                  <FamilyName>Tarlatzis</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>BC</Initials>
                  <FamilyName>Fauser</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>EM</Initials>
                  <FamilyName>Kolibianakis</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>K</Initials>
                  <FamilyName>Diedrich</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>L</Initials>
                  <FamilyName>Rombauts</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>P</Initials>
                  <FamilyName>Devroey</FamilyName>
                </BibAuthorName>
                <Year>2006</Year>
                <ArticleTitle Language="En">GnRH antagonists in ovarian stimulation for IVF</ArticleTitle>
                <JournalTitle>Hum Reprod Update</JournalTitle>
                <VolumeID>12</VolumeID>
                <FirstPage>333</FirstPage>
                <LastPage>340</LastPage>
                <Occurrence Type="PID">
                  <Handle>16567347</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD28Xmt1WktbY%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1093/humupd/dml001</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Tarlatzis BC, Fauser BC, Kolibianakis EM, Diedrich K, Rombauts L, Devroey P. GnRH antagonists in ovarian stimulation for IVF. Hum Reprod Update 2006;12:333–340.</BibUnstructured>
            </Citation>
            <Citation ID="CR39_2">
              <CitationNumber>39</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>RE</Initials>
                  <FamilyName>Armer</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>KH</Initials>
                  <FamilyName>Smelt</FamilyName>
                </BibAuthorName>
                <Year>2004</Year>
                <ArticleTitle Language="En">Non-peptidic GnRH receptor antagonists</ArticleTitle>
                <JournalTitle>Curr Med Chem</JournalTitle>
                <VolumeID>11</VolumeID>
                <FirstPage>3017</FirstPage>
                <LastPage>3026</LastPage>
                <Occurrence Type="PID">
                  <Handle>15544487</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2cXosVynur4%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.2174/0929867043363983</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Armer RE, Smelt KH. Non-peptidic GnRH receptor antagonists. Curr Med Chem 2004;11:3017–3026.</BibUnstructured>
            </Citation>
            <Citation ID="CR40_2">
              <CitationNumber>40</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Kovács</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Koppán</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>I</Initials>
                  <FamilyName>Mező</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>I</Initials>
                  <FamilyName>Teplán</FamilyName>
                </BibAuthorName>
                <Year>1994</Year>
                <ArticleTitle Language="En">Diverse effects of a potent LHRH antagonist on the LH and FSH release</ArticleTitle>
                <JournalTitle>Acta Biol Hung</JournalTitle>
                <VolumeID>45</VolumeID>
                <FirstPage>285</FirstPage>
                <LastPage>296</LastPage>
                <Occurrence Type="PID">
                  <Handle>7725823</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Kovács M, Koppán M, Mező I, Teplán I. Diverse effects of a potent LHRH antagonist on the LH and FSH release. Acta Biol Hung 1994;45:285–296.</BibUnstructured>
            </Citation>
            <Citation ID="CR41_2">
              <CitationNumber>41</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>L</Initials>
                  <FamilyName>Bokser</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>G</Initials>
                  <FamilyName>Srkalovic</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>K</Initials>
                  <FamilyName>Szepeshazi</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1991</Year>
                <ArticleTitle Language="En">Recovery of pituitary-gonadal function in male and female rats after prolonged administration of a potent antagonist of luteinizing hormone-releasing hormone (SB-75)</ArticleTitle>
                <JournalTitle>Neuroendocrinology</JournalTitle>
                <VolumeID>54</VolumeID>
                <FirstPage>136</FirstPage>
                <LastPage>145</LastPage>
                <Occurrence Type="PID">
                  <Handle>1662786</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK3MXltVKmt78%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1159/000125862</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Bokser L, Srkalovic G, Szepeshazi K, et al. Recovery of pituitary-gonadal function in male and female rats after prolonged administration of a potent antagonist of luteinizing hormone-releasing hormone (SB-75). Neuroendocrinology 1991;54:136–145.</BibUnstructured>
            </Citation>
            <Citation ID="CR42_2">
              <CitationNumber>42</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Pinski</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>T</Initials>
                  <FamilyName>Yano</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>K</Initials>
                  <FamilyName>Groot</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1992</Year>
                <ArticleTitle Language="En">Comparison of biological effects of a sustained delivery system and nonecapsulated LH-RH antagonist SB-75 in rats</ArticleTitle>
                <JournalTitle>Peptides</JournalTitle>
                <VolumeID>13</VolumeID>
                <FirstPage>905</FirstPage>
                <LastPage>911</LastPage>
                <Occurrence Type="PID">
                  <Handle>1336188</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK3sXms1Kqtg%3D%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/0196-9781(92)90048-8</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Pinski J, Yano T, Groot K, et al. Comparison of biological effects of a sustained delivery system and nonecapsulated LH-RH antagonist SB-75 in rats. Peptides 1992;13:905–911.</BibUnstructured>
            </Citation>
            <Citation ID="CR43_2">
              <CitationNumber>43</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>G</Initials>
                  <FamilyName>Halmos</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>AV</Initials>
                  <FamilyName>Schally</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Pinski</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1996</Year>
                <ArticleTitle Language="En">Down-regulation of pituitary receptors for luteinizing hormone-releasing hormone (LH-RH) in rats by LH-RH antagonist Cetrorelix</ArticleTitle>
                <JournalTitle>Proc Natl Acad Sci USA</JournalTitle>
                <VolumeID>93</VolumeID>
                <FirstPage>2398</FirstPage>
                <LastPage>2402</LastPage>
                <Occurrence Type="PID">
                  <Handle>8637885</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK28XhvVSkt7Y%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1073/pnas.93.6.2398</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Halmos G, Schally AV, Pinski J, et al. Down-regulation of pituitary receptors for luteinizing hormone-releasing hormone (LH-RH) in rats by LH-RH antagonist Cetrorelix. Proc Natl Acad Sci USA 1996;93:2398–2402.</BibUnstructured>
            </Citation>
            <Citation ID="CR44_2">
              <CitationNumber>44</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Pinski</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>N</Initials>
                  <FamilyName>Lamharzi</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>G</Initials>
                  <FamilyName>Halmos</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1996</Year>
                <ArticleTitle Language="En">Chronic administration of luteinizing hormone-releasing hormone (LHRH) antagonist Cetrorelix decreases gonadotrope responsiveness and pituitary LHRH receptor messenger ribonucleic acid levels in rats</ArticleTitle>
                <JournalTitle>Endocrinology</JournalTitle>
                <VolumeID>137</VolumeID>
                <FirstPage>3430</FirstPage>
                <LastPage>3436</LastPage>
                <Occurrence Type="PID">
                  <Handle>8754771</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK28XksVChsLs%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1210/en.137.8.3430</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Pinski J, Lamharzi N, Halmos G, et al. Chronic administration of luteinizing hormone-releasing hormone (LHRH) antagonist Cetrorelix decreases gonadotrope responsiveness and pituitary LHRH receptor messenger ribonucleic acid levels in rats. Endocrinology 1996;137:3430–3436.</BibUnstructured>
            </Citation>
            <Citation ID="CR45_2">
              <CitationNumber>45</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>HM</Initials>
                  <FamilyName>Behre</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Kliesch</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>G</Initials>
                  <FamilyName>Pühse</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1997</Year>
                <ArticleTitle Language="En">High loading and low maintenance doses of a gonadotropin-releasing hormone antagonist effectively suppress serum luteininzing hormone, follicle-stimulating hormone, and testosterone in normal men</ArticleTitle>
                <JournalTitle>J Clin Endocrinol Metab</JournalTitle>
                <VolumeID>82</VolumeID>
                <FirstPage>1403</FirstPage>
                <LastPage>1408</LastPage>
                <Occurrence Type="PID">
                  <Handle>9141524</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK2sXjtVGmtbY%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1210/jc.82.5.1403</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Behre HM, Kliesch S, Pühse G, et al. High loading and low maintenance doses of a gonadotropin-releasing hormone antagonist effectively suppress serum luteininzing hormone, follicle-stimulating hormone, and testosterone in normal men. J Clin Endocrinol Metab 1997;82:1403–1408.</BibUnstructured>
            </Citation>
            <Citation ID="CR46_2">
              <CitationNumber>46</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Qayum</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>W</Initials>
                  <FamilyName>Gullick</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>RC</Initials>
                  <FamilyName>Clayton</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>K</Initials>
                  <FamilyName>Sikora</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Waxman</FamilyName>
                </BibAuthorName>
                <Year>1990</Year>
                <ArticleTitle Language="En">The effects of gonadotropin-releasing hormone analogues in prostate cancer are mediated through specific tumour receptors</ArticleTitle>
                <JournalTitle>Br J Cancer</JournalTitle>
                <VolumeID>62</VolumeID>
                <FirstPage>96</FirstPage>
                <LastPage>99</LastPage>
                <Occurrence Type="PID">
                  <Handle>2117967</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK3MXktVWitL4%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1038/bjc.1990.236</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Qayum A, Gullick W, Clayton RC, Sikora K, Waxman J. The effects of gonadotropin-releasing hormone analogues in prostate cancer are mediated through specific tumour receptors. Br J Cancer 1990;62:96–99.</BibUnstructured>
            </Citation>
            <Citation ID="CR47_2">
              <CitationNumber>47</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>G</Initials>
                  <FamilyName>Halmos</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JM</Initials>
                  <FamilyName>Arenciba</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>AV</Initials>
                  <FamilyName>Schally</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>R</Initials>
                  <FamilyName>Davis</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DG</Initials>
                  <FamilyName>Bostwick</FamilyName>
                </BibAuthorName>
                <Year>2000</Year>
                <ArticleTitle Language="En">High incidence of receptors for luteinizing hormone-releasing hormone (LH-RH) and LH-RH receptor gene expression in human prostate cancers</ArticleTitle>
                <JournalTitle>J Urology</JournalTitle>
                <VolumeID>163</VolumeID>
                <FirstPage>623</FirstPage>
                <LastPage>629</LastPage>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3cXns1OntA%3D%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/S0022-5347(05)67947-5</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Halmos G, Arenciba JM, Schally AV, Davis R, Bostwick DG. High incidence of receptors for luteinizing hormone-releasing hormone (LH-RH) and LH-RH receptor gene expression in human prostate cancers. J Urology 2000;163:623–629.</BibUnstructured>
            </Citation>
            <Citation ID="CR48_2">
              <CitationNumber>48</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>B</Initials>
                  <FamilyName>Straub</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Müller</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>H</Initials>
                  <FamilyName>Krause</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2001</Year>
                <ArticleTitle Language="En">Increased incidence of LHRH receptor gene messenger RNA expression in hormone-refractory human prostate cancers</ArticleTitle>
                <JournalTitle>Clin Cancer Res</JournalTitle>
                <VolumeID>7</VolumeID>
                <FirstPage>2340</FirstPage>
                <LastPage>2343</LastPage>
                <Occurrence Type="PID">
                  <Handle>11489810</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3MXmsVOmt7o%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Straub B, Müller M, Krause H, et al. Increased incidence of LHRH receptor gene messenger RNA expression in hormone-refractory human prostate cancers. Clin Cancer Res 2001;7:2340–2343.</BibUnstructured>
            </Citation>
            <Citation ID="CR49_2">
              <CitationNumber>49</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>P</Initials>
                  <FamilyName>Limonta</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>D</Initials>
                  <FamilyName>Dondi</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Roberta</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1993</Year>
                <ArticleTitle Language="En">Expression of luteinizing hormone-releasing hormone mRNA in the human prostatic cancer cell line LNCaP</ArticleTitle>
                <JournalTitle>J Clin Endocrinol Metab</JournalTitle>
                <VolumeID>76</VolumeID>
                <FirstPage>797</FirstPage>
                <LastPage>800</LastPage>
                <Occurrence Type="PID">
                  <Handle>8445038</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK3sXks12hsrw%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1210/jc.76.3.797</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Limonta P, Dondi D, Roberta M, et al. Expression of luteinizing hormone-releasing hormone mRNA in the human prostatic cancer cell line LNCaP. J Clin Endocrinol Metab 1993;76:797–800.</BibUnstructured>
            </Citation>
            <Citation ID="CR50_2">
              <CitationNumber>50</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>AV</Initials>
                  <FamilyName>Schally</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>G</Initials>
                  <FamilyName>Halmos</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>Z</Initials>
                  <FamilyName>Rekasi</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JM</Initials>
                  <FamilyName>Arencibia-Jimenez</FamilyName>
                </BibAuthorName>
                <Year>2001</Year>
                <ArticleTitle Language="En">The actions of luteinizing hormone-releasing hormone agonists, antagonists, and cytotoxic analogues on the luteinizing hormone-releasing hormone receptors on the pituitary and tumors</ArticleTitle>
                <JournalTitle>Infertility Reprod Med Clin North Am</JournalTitle>
                <VolumeID>12</VolumeID>
                <FirstPage>17</FirstPage>
                <LastPage>44</LastPage>
              </BibArticle>
              <BibUnstructured>Schally AV, Halmos G, Rekasi Z, Arencibia-Jimenez JM. The actions of luteinizing hormone-releasing hormone agonists, antagonists, and cytotoxic analogues on the luteinizing hormone-releasing hormone receptors on the pituitary and tumors. Infert Reprod Med Clin North Amer 2001;12:17–44.</BibUnstructured>
            </Citation>
            <Citation ID="CR51_2">
              <CitationNumber>51</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>KA</Initials>
                  <FamilyName>Eidne</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>CA</Initials>
                  <FamilyName>Flanagan</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>RP</Initials>
                  <FamilyName>Millar</FamilyName>
                </BibAuthorName>
                <Year>1985</Year>
                <ArticleTitle Language="En">Gonadotropin-releasing hormone binding sites in human breast carcinoma</ArticleTitle>
                <JournalTitle>Science</JournalTitle>
                <VolumeID>229</VolumeID>
                <FirstPage>989</FirstPage>
                <LastPage>991</LastPage>
                <Occurrence Type="PID">
                  <Handle>2992093</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaL2MXlsFygt7Y%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1126/science.2992093</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Eidne KA, Flanagan CA, Millar RP. Gonadotropin-releasing hormone binding sites in human breast carcinoma. Science 1985;229:989–991.</BibUnstructured>
            </Citation>
            <Citation ID="CR52_2">
              <CitationNumber>52</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>WR</Initials>
                  <FamilyName>Miller</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>WN</Initials>
                  <FamilyName>Scott</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>R</Initials>
                  <FamilyName>Morris</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>HM</Initials>
                  <FamilyName>Fraser</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>RM</Initials>
                  <FamilyName>Sharpe</FamilyName>
                </BibAuthorName>
                <Year>1985</Year>
                <ArticleTitle Language="En">Growth of human breast cancer cells inhibited by a luteinizing hormone-releasing hormone agonist</ArticleTitle>
                <JournalTitle>Nature</JournalTitle>
                <VolumeID>313</VolumeID>
                <FirstPage>231</FirstPage>
                <LastPage>233</LastPage>
                <Occurrence Type="PID">
                  <Handle>2982100</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaL2MXhtVKltL0%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1038/313231a0</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Miller WR, Scott WN, Morris R, Fraser HM, Sharpe RM. Growth of human breast cancer cells inhibited by a luteinizing hormone-releasing hormone agonist. Nature 1985;313:231–233.</BibUnstructured>
            </Citation>
            <Citation ID="CR53_2">
              <CitationNumber>53</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Fekete</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JL</Initials>
                  <FamilyName>Wittliff</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>AV</Initials>
                  <FamilyName>Schally</FamilyName>
                </BibAuthorName>
                <Year>1989</Year>
                <ArticleTitle Language="En">Characteristics and distribution of receptors for [D-Trp<Superscript>6</Superscript>]-luteinizing hormone-releasing hormone, somatostatin, epidermal growth factor and sex steroids in 500 biopsy samples of human breast cancer</ArticleTitle>
                <JournalTitle>J Clin Lab Anal</JournalTitle>
                <VolumeID>3</VolumeID>
                <FirstPage>137</FirstPage>
                <LastPage>147</LastPage>
                <Occurrence Type="PID">
                  <Handle>2569034</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaL1MXktFygsr0%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1002/jcla.1860030302</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Fekete M, Wittliff JL, Schally AV. Characteristics and distribution of receptors for [D-Trp<Superscript>6</Superscript>]-luteinizing hormone-releasing hormone, somatostatin, epidermal growth factor and sex steroids in 500 biopsy samples of human breast cancer. J Clin Lab Anal 1989;3:137–147.</BibUnstructured>
            </Citation>
            <Citation ID="CR54_2">
              <CitationNumber>54</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>G</Initials>
                  <FamilyName>Emons</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>AV</Initials>
                  <FamilyName>Schally</FamilyName>
                </BibAuthorName>
                <Year>1994</Year>
                <ArticleTitle Language="En">The use of luteinizing hormone releaseing hormone agonists and antagonists in gynaecological cancers</ArticleTitle>
                <JournalTitle>Reproduction</JournalTitle>
                <VolumeID>9</VolumeID>
                <FirstPage>1364</FirstPage>
                <LastPage>1379</LastPage>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DyaK2M%2FltFCgtA%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Emons G, Schally AV. The use of luteinizing hormone releaseing hormone agonists and antagonists in gynaecological cancers. Reproduction 1994;9:1364–1379.</BibUnstructured>
            </Citation>
            <Citation ID="CR55_2">
              <CitationNumber>55</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>G</Initials>
                  <FamilyName>Srkalovic</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>AV</Initials>
                  <FamilyName>Schally</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JL</Initials>
                  <FamilyName>Wittliff</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>G</Initials>
                  <FamilyName>Day</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>EL</Initials>
                  <FamilyName>Jenison</FamilyName>
                </BibAuthorName>
                <Year>1998</Year>
                <ArticleTitle Language="En">Presence and characteristics of receptors for [D-Trp<Superscript>6</Superscript>]-luteinizing hormone-releasing hormone and epidermal growth factor in human ovarian cancer</ArticleTitle>
                <JournalTitle>Int J Oncol</JournalTitle>
                <VolumeID>12</VolumeID>
                <FirstPage>489</FirstPage>
                <LastPage>498</LastPage>
                <Occurrence Type="PID">
                  <Handle>9472084</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK1cXitVSrsrw%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Srkalovic G, Schally AV, Wittliff JL, Day G, Jenison EL. Presence and characteristics of receptors for [D-Trp<Superscript>6</Superscript>]-luteinizing hormone-releasing hormone and epidermal growth factor in human ovarian cancer. Int J Oncol 1998;12:489–498.</BibUnstructured>
            </Citation>
            <Citation ID="CR56_2">
              <CitationNumber>56</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>G</Initials>
                  <FamilyName>Srkalovic</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JL</Initials>
                  <FamilyName>Wittliff</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>AV</Initials>
                  <FamilyName>Schally</FamilyName>
                </BibAuthorName>
                <Year>1990</Year>
                <ArticleTitle Language="En">Detection and partial characterization of receptors for [D-Trp6]luteinizing hormone-releasing hormone in human endometrial carcinoma</ArticleTitle>
                <JournalTitle>Cancer Res</JournalTitle>
                <VolumeID>50</VolumeID>
                <FirstPage>1841</FirstPage>
                <LastPage>1846</LastPage>
                <Occurrence Type="PID">
                  <Handle>2155060</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK3cXitleitrc%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Srkalovic G, Wittliff JL, Schally AV. Detection and partial characterization of receptors for [D-Trp6]luteinizing hormone-releasing hormone in human endometrial carcinoma. Cancer Res 1990;50:1841–1846.</BibUnstructured>
            </Citation>
            <Citation ID="CR57_2">
              <CitationNumber>57</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>JB</Initials>
                  <FamilyName>Engel</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>AV</Initials>
                  <FamilyName>Schally</FamilyName>
                </BibAuthorName>
                <Year>2007</Year>
                <ArticleTitle Language="En">Drug insight: Clinical use of agonists and antagonists of luteinizing hormone-releasing hormone</ArticleTitle>
                <JournalTitle>Nat Clin Pract Endocrinol Metab</JournalTitle>
                <VolumeID>3</VolumeID>
                <FirstPage>157</FirstPage>
                <LastPage>167</LastPage>
                <Occurrence Type="PID">
                  <Handle>17237842</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2sXhvVWrsb8%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1038/ncpendmet0399</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Engel J B, Schally AV. Drug insight: clinical use of agonists and antagonists of luteinizing hormone-releasing hormone. Nat Clin Pract Endocrinol Metab 2007;3:157–167.</BibUnstructured>
            </Citation>
            <Citation ID="CR58_2">
              <CitationNumber>58</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>G</Initials>
                  <FamilyName>Emons</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>O</Initials>
                  <FamilyName>Ortmann</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>KD</Initials>
                  <FamilyName>Schulz</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1997</Year>
                <ArticleTitle Language="En">Growth-inhibitory actions of analogues of luteinizing hormone releasing hormone on tumor cells</ArticleTitle>
                <JournalTitle>Trends Endocrinol Metab</JournalTitle>
                <VolumeID>8</VolumeID>
                <FirstPage>355</FirstPage>
                <LastPage>362</LastPage>
                <Occurrence Type="PID">
                  <Handle>18406825</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK1cXhvFWgsw%3D%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/S1043-2760(97)00155-0</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Emons G, Ortmann O, Schulz KD, et al. Growth-inhibitory actions of analogues of luteinizing hormone releasing hormone on tumor cells. Trends Endocrinol Metab 1997;8:355–362.</BibUnstructured>
            </Citation>
            <Citation ID="CR59_2">
              <CitationNumber>59</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>G</Initials>
                  <FamilyName>Irmer</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>C</Initials>
                  <FamilyName>Burger</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>O</Initials>
                  <FamilyName>Ortmann</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>KD</Initials>
                  <FamilyName>Schulz</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>G</Initials>
                  <FamilyName>Emmons</FamilyName>
                </BibAuthorName>
                <Year>1994</Year>
                <ArticleTitle Language="En">Expression of luteinizing hormone-releasing hormone and its mRNA in human endometrial cancer cell lines</ArticleTitle>
                <JournalTitle>J Clin Endocrinol Metab</JournalTitle>
                <VolumeID>79</VolumeID>
                <FirstPage>916</FirstPage>
                <LastPage>919</LastPage>
                <Occurrence Type="PID">
                  <Handle>8077383</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK2cXmt1ans7w%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1210/jc.79.3.916</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Irmer G, Burger C, Ortmann O, Schulz KD, Emmons G. Expression of luteinizing hormone-releasing hormone and its mRNA in human endometrial cancer cell lines. J Clin Endocrinol Metab 1994;79:916–919.</BibUnstructured>
            </Citation>
            <Citation ID="CR60_2">
              <CitationNumber>60</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>NS</Initials>
                  <FamilyName>Harris</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>C</Initials>
                  <FamilyName>Dutlow</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>K</Initials>
                  <FamilyName>Eidne</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1991</Year>
                <ArticleTitle Language="En">Gonadotropin-releasing hormone gene expression in MDA-MB-231 and ZR-75-1 breast carcinoma cell lines</ArticleTitle>
                <JournalTitle>Cancer Res</JournalTitle>
                <VolumeID>51</VolumeID>
                <FirstPage>2577</FirstPage>
                <LastPage>2581</LastPage>
                <Occurrence Type="PID">
                  <Handle>2021939</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK3MXktVKju70%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Harris NS, Dutlow C, Eidne K, et al. Gonadotropin-releasing hormone gene expression in MDA-MB-231 and ZR-75-1 breast carcinoma cell lines. Cancer Res 1991;51:2577–2581.</BibUnstructured>
            </Citation>
            <Citation ID="CR61_2">
              <CitationNumber>61</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>G</Initials>
                  <FamilyName>Emons</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>V</Initials>
                  <FamilyName>Müller</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>O</Initials>
                  <FamilyName>Ortmann</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>KD</Initials>
                  <FamilyName>Schultz</FamilyName>
                </BibAuthorName>
                <Year>1998</Year>
                <ArticleTitle Language="En">Effects of LHRH analogues on mitogenic signal transduction in cancer cells</ArticleTitle>
                <JournalTitle>J Steroid Biochem Mol Biol</JournalTitle>
                <VolumeID>65</VolumeID>
                <FirstPage>199</FirstPage>
                <LastPage>205</LastPage>
                <Occurrence Type="PID">
                  <Handle>9699874</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK1cXkvVKqsr0%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/S0960-0760(97)00189-1</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Emons G, Müller V, Ortmann O, Schultz KD. Effects of LHRH analogues on mitogenic signal transduction in cancer cells. J Steroid Biochem Mol Biol 1998;65:199–205.</BibUnstructured>
            </Citation>
            <Citation ID="CR62_2">
              <CitationNumber>62</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>X</Initials>
                  <FamilyName>Tang</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>T</Initials>
                  <FamilyName>Yano</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>Y</Initials>
                  <FamilyName>Osuga</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2002</Year>
                <ArticleTitle Language="En">Cellular mechanisms of growth inhibition of human epithelial ovarian cancer cell line by LH-releasing hormone antagonist Cetrorelix</ArticleTitle>
                <JournalTitle>J Clin Endocrinol Metab</JournalTitle>
                <VolumeID>87</VolumeID>
                <FirstPage>3721</FirstPage>
                <LastPage>3727</LastPage>
                <Occurrence Type="PID">
                  <Handle>12161501</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD38XmtF2gtr0%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1210/jc.87.8.3721</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Tang X, Yano T, Osuga Y, et al. Cellular mechanisms of growth inhibition of human epithelial ovarian cancer cell line by LH-releasing hormone antagonist Cetrorelix. J Clin Endocrinol Metab 2002;87:3721–3727.</BibUnstructured>
            </Citation>
            <Citation ID="CR63_2">
              <CitationNumber>63</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>Y</Initials>
                  <FamilyName>Sharoni</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>E</Initials>
                  <FamilyName>Bosin</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Minster</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1989</Year>
                <ArticleTitle Language="En">Inhibition of growth of human mammary tumor cells by potent antagonists of luteinizing hormone-releasing hormone</ArticleTitle>
                <JournalTitle>Proc Natl Acad Sci USA</JournalTitle>
                <VolumeID>86</VolumeID>
                <FirstPage>1648</FirstPage>
                <LastPage>1651</LastPage>
                <Occurrence Type="PID">
                  <Handle>2646641</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaL1MXitVKjtbg%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1073/pnas.86.5.1648</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Sharoni Y, Bosin E, Minster A, et al. Inhibition of growth of human mammary tumor cells by potent antagonists of luteinizing hormone-releasing hormone. Proc Natl Acad Sci USA 1989;86:1648–1651.</BibUnstructured>
            </Citation>
            <Citation ID="CR64_2">
              <CitationNumber>64</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>D</Initials>
                  <FamilyName>Dondi</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>P</Initials>
                  <FamilyName>Limonta</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>RM</Initials>
                  <FamilyName>Moretti</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MM</Initials>
                  <FamilyName>Marelli</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>E</Initials>
                  <FamilyName>Garattini</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Motta</FamilyName>
                </BibAuthorName>
                <Year>1994</Year>
                <ArticleTitle Language="En">Antiproliferative effects of LHRH agonists on the human androgen-independent prostate cancer cell line DU 145: Evidence for an autocrine inhibitory LHRH loop</ArticleTitle>
                <JournalTitle>Cancer Res</JournalTitle>
                <VolumeID>54</VolumeID>
                <FirstPage>4091</FirstPage>
                <LastPage>4095</LastPage>
                <Occurrence Type="PID">
                  <Handle>8033142</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK2cXltVShtb8%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Dondi D, Limonta P, Moretti RM, Marelli MM, Garattini E, Motta M. Antiproliferative effects of LHRH agonists on the human androgen-independent prostate cancer cell line DU 145: Evidence for an autocrine inhibitory LHRH loop. Cancer Res 1994;54:4091–4095.</BibUnstructured>
            </Citation>
            <Citation ID="CR65_2">
              <CitationNumber>65</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>BE</Initials>
                  <FamilyName>Hawes</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>PM</Initials>
                  <FamilyName>Conn</FamilyName>
                </BibAuthorName>
                <Year>1993</Year>
                <ArticleTitle Language="En">Assessment of the role of G proteins and inositol phosphate production in the action of gonadotropin-releasing hormone</ArticleTitle>
                <JournalTitle>Clin Chem</JournalTitle>
                <VolumeID>39</VolumeID>
                <FirstPage>325</FirstPage>
                <LastPage>332</LastPage>
                <Occurrence Type="PID">
                  <Handle>8432023</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK3sXhvVemt74%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Hawes BE, Conn PM. Assessment of the role of G proteins and inositol phosphate production in the action of gonadotropin-releasing hormone. Clin Chem 1993;39:325–332.</BibUnstructured>
            </Citation>
            <Citation ID="CR66_2">
              <CitationNumber>66</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>P</Initials>
                  <FamilyName>Völker</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>C</Initials>
                  <FamilyName>Gründker</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>O</Initials>
                  <FamilyName>Schmidt</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>K-D</Initials>
                  <FamilyName>Schultz</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>G</Initials>
                  <FamilyName>Emons</FamilyName>
                </BibAuthorName>
                <Year>2002</Year>
                <ArticleTitle Language="En">Expression of receptors for luteinizing hormone-releasing hormone in human ovarian and endometrial cancers: Frequency, autoregulation, and correlation with direct antirpoliferative activity of luteinizing hormone-releasing hormone analogs</ArticleTitle>
                <JournalTitle>Am J Obstet Gynecol</JournalTitle>
                <VolumeID>186</VolumeID>
                <FirstPage>171</FirstPage>
                <LastPage>179</LastPage>
                <Occurrence Type="PID">
                  <Handle>11854630</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1067/mob.2002.119633</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD38Xit1Wnsrk%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Völker P, Gründker C, Schmidt O, Schultz K-D, Emons G. Expression of receptors for luteinizing hormone-releasing hormone in human ovarian and endometrial cancers: Frequency, autoregulation, and correlation with direct antirpoliferative activity of luteinizing hormone-releasing hormone analogs. Am J Obstet Gynecol 2002;186:171–179.</BibUnstructured>
            </Citation>
            <Citation ID="CR67_2">
              <CitationNumber>67</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>KR</Initials>
                  <FamilyName>Shedgley</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>AR</Initials>
                  <FamilyName>Finch</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>CJ</Initials>
                  <FamilyName>Caunt</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>CA</Initials>
                  <FamilyName>McArdle</FamilyName>
                </BibAuthorName>
                <Year>2006</Year>
                <ArticleTitle Language="En">Intracellular gonadotropin-releasing hormone receptors in breast and gonadotrope lineage cells</ArticleTitle>
                <JournalTitle>J Endocrinol</JournalTitle>
                <VolumeID>191</VolumeID>
                <FirstPage>625</FirstPage>
                <LastPage>636</LastPage>
                <Occurrence Type="DOI">
                  <Handle>10.1677/joe.1.07067</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2sXht1egu7Y%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Shedgley KR, Finch AR, Caunt CJ, McArdle CA. Intracellular gonadotropin-releasing hormone receptors in breast and gonadotrope lineage cells. J Endocrinol 2006;191:625–636.</BibUnstructured>
            </Citation>
            <Citation ID="CR68_2">
              <CitationNumber>68</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>CK</Initials>
                  <FamilyName>Cheng</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>PCK</Initials>
                  <FamilyName>Leung</FamilyName>
                </BibAuthorName>
                <Year>2005</Year>
                <ArticleTitle Language="En">Molecular biology of gonadotropin-releasing hormone (GnRH)-I, GnRH-II, and their receptors in humans</ArticleTitle>
                <JournalTitle>Endocr Rev</JournalTitle>
                <VolumeID>26</VolumeID>
                <FirstPage>283</FirstPage>
                <LastPage>306</LastPage>
                <Occurrence Type="PID">
                  <Handle>15561800</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2MXjslGjtr0%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1210/er.2003-0039</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Cheng CK, Leung PCK. Molecular biology of gonadotropin-releasing hormone (GnRH)-I, GnRH-II, and their receptors in humans. Endocr Rev 2005;26:283–306.</BibUnstructured>
            </Citation>
            <Citation ID="CR69_2">
              <CitationNumber>69</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>C</Initials>
                  <FamilyName>Gründker</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>AR</Initials>
                  <FamilyName>Gunthert</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Westphalen</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>G</Initials>
                  <FamilyName>Emons</FamilyName>
                </BibAuthorName>
                <Year>2002</Year>
                <ArticleTitle Language="En">Biology of the gonadotropin-releasing hormone system in gynecological cancers</ArticleTitle>
                <JournalTitle>Eur J Endocrinol</JournalTitle>
                <VolumeID>146</VolumeID>
                <FirstPage>1</FirstPage>
                <LastPage>14</LastPage>
                <Occurrence Type="PID">
                  <Handle>11751060</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1530/eje.0.1460001</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Gründker C, Gunthert AR, Westphalen S, Emons G. Biology of the gonadotropin-releasing hormone system in gynecological cancers. Eur J Endocrinol 2002;146:1–14.</BibUnstructured>
            </Citation>
            <Citation ID="CR70_2">
              <CitationNumber>70</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>G</Initials>
                  <FamilyName>Emons</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>C</Initials>
                  <FamilyName>Grundker</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>AR</Initials>
                  <FamilyName>Gunthert</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Westphalen</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Kavanagh</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>C</Initials>
                  <FamilyName>Verschraegen</FamilyName>
                </BibAuthorName>
                <Year>2003</Year>
                <ArticleTitle Language="En">GnRH antagonists in the treatment of gynecological and breast cancers</ArticleTitle>
                <JournalTitle>Endocr Relat Cancer</JournalTitle>
                <VolumeID>10</VolumeID>
                <FirstPage>291</FirstPage>
                <LastPage>299</LastPage>
                <Occurrence Type="PID">
                  <Handle>12790790</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3sXmsFCrs70%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1677/erc.0.0100291</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Emons G, Grundker C, Gunthert AR, Westphalen S, Kavanagh J, Verschraegen C. GnRH antagonists in the treatment of gynecological and breast cancers. Endocr Relat Cancer 2003;10:291–299.</BibUnstructured>
            </Citation>
            <Citation ID="CR71_2">
              <CitationNumber>71</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>AV</Initials>
                  <FamilyName>Schally</FamilyName>
                </BibAuthorName>
                <Year>1999</Year>
                <ArticleTitle Language="En">LH-RH analogues. I. Their impact on reproductive medicine</ArticleTitle>
                <JournalTitle>Gynecol Endocrinol</JournalTitle>
                <VolumeID>13</VolumeID>
                <FirstPage>401</FirstPage>
                <LastPage>409</LastPage>
                <Occurrence Type="PID">
                  <Handle>10685334</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DC%2BD3c7kvFGqtw%3D%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.3109/09513599909167587</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Schally AV. LH-RH analogues. I. Their impact on reproductive medicine. Gynecol Endocrinol 1999;13:401–409.</BibUnstructured>
            </Citation>
            <Citation ID="CR72_2">
              <CitationNumber>72</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>AV</Initials>
                  <FamilyName>Schally</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>AM</Initials>
                  <FamilyName>Comaru-Schally</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Plonowski</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Nagy</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>G</Initials>
                  <FamilyName>Halmos</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>Z</Initials>
                  <FamilyName>Rekasi</FamilyName>
                </BibAuthorName>
                <Year>2000</Year>
                <ArticleTitle Language="En">Peptide analogs in the therapy of prostate cancer</ArticleTitle>
                <JournalTitle>Prostate</JournalTitle>
                <VolumeID>45</VolumeID>
                <FirstPage>158</FirstPage>
                <LastPage>166</LastPage>
                <Occurrence Type="PID">
                  <Handle>11027415</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3cXnsFGisrc%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1002/1097-0045(20001001)45:2&lt;158::AID-PROS10&gt;3.0.CO;2-K</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Schally AV, Comaru-Schally AM, Plonowski A, Nagy A, Halmos G, Rekasi Z. Peptide analogs in the therapy of prostate cancer. Prostate 2000;45:158–166.</BibUnstructured>
            </Citation>
            <Citation ID="CR73_2">
              <CitationNumber>73</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>AV</Initials>
                  <FamilyName>Schally</FamilyName>
                </BibAuthorName>
                <Year>2007</Year>
                <ArticleTitle Language="En">Luteinizing hormone-releasing hormone analogues and hormone ablation for prostate cancer: state of the art</ArticleTitle>
                <JournalTitle>Br J Urol</JournalTitle>
                <VolumeID>100</VolumeID>
                <IssueID>S2</IssueID>
                <FirstPage>2</FirstPage>
                <LastPage>4</LastPage>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2sXpsVCrtbc%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Schally AV. Luteinizing hormone-releasing hormone analogues and hormone ablation for prostate cancer: state of the art. Br J Urol 2007;100(S2):2–4.</BibUnstructured>
            </Citation>
            <Citation ID="CR74_2">
              <CitationNumber>74</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>D</Initials>
                  <FamilyName>Gonzalez-Barcena</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Vadillo-Buenfil</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>F</Initials>
                  <FamilyName>Gomez-Orta</FamilyName>
                </BibAuthorName>
                <Year>1994</Year>
                <ArticleTitle Language="En">Responses to the antagonistic analog of LHRH (Cetrorelix) in patients with benign prostatic hyperplasia and prostatic cancer</ArticleTitle>
                <JournalTitle>Prostate</JournalTitle>
                <VolumeID>24</VolumeID>
                <FirstPage>84</FirstPage>
                <LastPage>92</LastPage>
                <Occurrence Type="PID">
                  <Handle>7508623</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DyaK2c7ktlagtA%3D%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1002/pros.2990240206</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Gonzalez-Barcena D, Vadillo-Buenfil M, Gomez-Orta F. Responses to the antagonistic analog of LHRH (Cetrorelix) in patients with benign prostatic hyperplasia and prostatic cancer. Prostate 1994;24:84–92.</BibUnstructured>
            </Citation>
            <Citation ID="CR75_2">
              <CitationNumber>75</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>AM</Initials>
                  <FamilyName>Comaru-Schally</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>W</Initials>
                  <FamilyName>Brannan</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>AV</Initials>
                  <FamilyName>Schally</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Colcolough</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Monga</FamilyName>
                </BibAuthorName>
                <Year>1998</Year>
                <ArticleTitle Language="En">Efficacy and safety of luteinizing hormone-releasing hormone antagonist Cetrorelix in the treatment of symptomatic benign prostatic hyperplasia</ArticleTitle>
                <JournalTitle>J Clin Endocrinol Metab</JournalTitle>
                <VolumeID>83</VolumeID>
                <FirstPage>3826</FirstPage>
                <LastPage>3831</LastPage>
                <Occurrence Type="PID">
                  <Handle>9814453</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK1cXntlOisbw%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1210/jc.83.11.3826</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Comaru-Schally AM, Brannan W, Schally AV, Colcolough M, Monga M. Efficacy and safety of luteinizing hormone-releasing hormone antagonist Cetrorelix in the treatment of symptomatic benign prostatic hyperplasia. J Clin Endocrinol Metab1998;83:3826–3831.</BibUnstructured>
            </Citation>
            <Citation ID="CR76_2">
              <CitationNumber>76</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>F</Initials>
                  <FamilyName>Debruyne</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>AA</Initials>
                  <FamilyName>Gress</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DL</Initials>
                  <FamilyName>Arustamov</FamilyName>
                </BibAuthorName>
                <Year>2008</Year>
                <ArticleTitle Language="En">Placebo-controlled dose-ranging phase 2 study of subcutaneously administered LHRH antagonist cetrorelix in patients with symptomatic benign prostatic hyperplasia</ArticleTitle>
                <JournalTitle>Eur Urol</JournalTitle>
                <VolumeID>54</VolumeID>
                <FirstPage>170</FirstPage>
                <LastPage>177</LastPage>
                <Occurrence Type="PID">
                  <Handle>18417275</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD1cXptFSns7c%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/j.eururo.2008.03.069</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Debruyne F, Gress AA, Arustamov DL. Placebo-controlled dose-ranging phase 2 study of subcutaneously administered LHRH antagonist cetrorelix in patients with symptomatic benign prostatic hyperplasia. Eur Urol 2008;54:170–177.</BibUnstructured>
            </Citation>
            <Citation ID="CR77_2">
              <CitationNumber>77</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>JE</Initials>
                  <FamilyName>Horvath</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>GL</Initials>
                  <FamilyName>Toller</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>AV</Initials>
                  <FamilyName>Schally</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>AM</Initials>
                  <FamilyName>Bajo</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>K</Initials>
                  <FamilyName>Groot</FamilyName>
                </BibAuthorName>
                <Year>2004</Year>
                <ArticleTitle Language="En">Effect of long-term treatment with low doses of the LHRH antagonist Cetrorelix on pituitary receptors for LHRH and gonadal axis in male and female rats</ArticleTitle>
                <JournalTitle>PNAS</JournalTitle>
                <VolumeID>101</VolumeID>
                <FirstPage>4996</FirstPage>
                <LastPage>5001</LastPage>
                <Occurrence Type="PID">
                  <Handle>15044692</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2cXjsFCis7Y%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1073/pnas.0400605101</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Horvath JE, Toller GL, Schally AV, Bajo AM, Groot K. Effect of long-term treatment with low doses of the LHRH antagonist Cetrorelix on pituitary receptors for LHRH and gonadal axis in male and female rats. PNAS 2004;101:4996–5001.</BibUnstructured>
            </Citation>
            <Citation ID="CR78_2">
              <CitationNumber>78</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Nagy</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>AV</Initials>
                  <FamilyName>Schally</FamilyName>
                </BibAuthorName>
                <Year>2005</Year>
                <ArticleTitle Language="En">Targeting of cytotoxic LHRH analogs to breast, ovarian, endometrial and prostate cancers</ArticleTitle>
                <JournalTitle>Biol Reprod</JournalTitle>
                <VolumeID>73</VolumeID>
                <FirstPage>851</FirstPage>
                <LastPage>859</LastPage>
                <Occurrence Type="PID">
                  <Handle>16033997</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2MXhtFGktLfE</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1095/biolreprod.105.043489</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Nagy A, Schally AV. Targeting of cytotoxic LHRH analogs to breast, ovarian, endometrial and prostate cancers. Biol Reprod 2005;73:851–859.</BibUnstructured>
            </Citation>
            <Citation ID="CR79_2">
              <CitationNumber>79</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Nagy</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>AV</Initials>
                  <FamilyName>Schally</FamilyName>
                </BibAuthorName>
                <Year>2004</Year>
                <ArticleTitle Language="En">Targeting cytotoxic conjugates of somatostatin, luteinizing hormone-releasing hormone and bombesin to cancers expressing their receptors: A “smarter” chemotherapy</ArticleTitle>
                <JournalTitle>Curr Pharm Des</JournalTitle>
                <VolumeID>14</VolumeID>
                <FirstPage>1167</FirstPage>
                <LastPage>1180</LastPage>
              </BibArticle>
              <BibUnstructured>Nagy A, Schally AV. Targeting cytotoxic conjugates of somatostatin, luteinizing hormone-releasing hormone and bombesin to cancers expressing their receptors: A “smarter” chemotherapy. Curr Pharm Des 2004;14:1167–1180.</BibUnstructured>
            </Citation>
            <Citation ID="CR80_2">
              <CitationNumber>80</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Nagy</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>AV</Initials>
                  <FamilyName>Schally</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>P</Initials>
                  <FamilyName>Armatis</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1996</Year>
                <ArticleTitle Language="En">Cytotoxic analogs of luteinizing hormone-releasing hormone containing doxorubicin or 2-pyrrolinodoxorubicin, a derivative 500–1000 times more potent</ArticleTitle>
                <JournalTitle>Proc Natl Acad Sci USA</JournalTitle>
                <VolumeID>93</VolumeID>
                <FirstPage>7269</FirstPage>
                <LastPage>7273</LastPage>
                <Occurrence Type="PID">
                  <Handle>8692981</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK28Xkt1WgsbY%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1073/pnas.93.14.7269</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Nagy A, Schally AV, Armatis P, et al. Cytotoxic analogs of luteinizing hormone-releasing hormone containing doxorubicin or 2-pyrrolinodoxorubicin, a derivative 500-1000 times more potent. Proc Natl Acad Sci USA 1996;93:7269–7273.</BibUnstructured>
            </Citation>
            <Citation ID="CR81_2">
              <CitationNumber>81</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>R</Initials>
                  <FamilyName>Eaveri</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Ben-Yehudah</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>H</Initials>
                  <FamilyName>Lorberboum-Galski</FamilyName>
                </BibAuthorName>
                <Year>2004</Year>
                <ArticleTitle Language="En">Surface antigens/receptors for targeted cancer treatment: The GnRH receptor/binding site for targeted adenocarcinoma therapy</ArticleTitle>
                <JournalTitle>Curr Cancer Drug Targets</JournalTitle>
                <VolumeID>4</VolumeID>
                <FirstPage>673</FirstPage>
                <LastPage>687</LastPage>
                <Occurrence Type="PID">
                  <Handle>15578922</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2MXhtVygtQ%3D%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.2174/1568009043332745</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Eaveri R, Ben-Yehudah A, Lorberboum-Galski H. Surface antigens/receptors for targeted cancer treatment: the GnRH receptor/binding site for targeted adenocarcinoma therapy. Curr Cancer Drug Targets 2004;4:673–687.</BibUnstructured>
            </Citation>
            <Citation ID="CR82_2">
              <CitationNumber>82</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>X</Initials>
                  <FamilyName>Wang</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>LJ</Initials>
                  <FamilyName>Krebs</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Al-Nuri</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1999</Year>
                <ArticleTitle Language="En">A chemically labeled cytotoxic agent: Two-photon fluorophore for optical tracking of cellular pathway in chemotherapy</ArticleTitle>
                <JournalTitle>Proc Natl Acad Sci USA</JournalTitle>
                <VolumeID>96</VolumeID>
                <FirstPage>11081</FirstPage>
                <LastPage>11084</LastPage>
                <Occurrence Type="PID">
                  <Handle>10500132</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK1MXmvVCnur4%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1073/pnas.96.20.11081</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Wang X, Krebs LJ, Al-Nuri M, et al. A chemically labeled cytotoxic agent: Two-photon fluorophore for optical tracking of cellular pathway in chemotherapy. Proc Natl Acad Sci USA 1999;96:11081–11084.</BibUnstructured>
            </Citation>
            <Citation ID="CR83_2">
              <CitationNumber>83</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>AR</Initials>
                  <FamilyName>Gunthert</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>C</Initials>
                  <FamilyName>Grundker</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>T</Initials>
                  <FamilyName>Bongertz</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>T</Initials>
                  <FamilyName>Schlott</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Nagy</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>AV</Initials>
                  <FamilyName>Schally</FamilyName>
                </BibAuthorName>
                <Year>2004</Year>
                <ArticleTitle Language="En">Internalization of cytotoxic luteinizing hormone-releasing hormone analog AN-152 induces multi drug resistance 1 (MDR-1) independent apoptosis in human endometrial and ovarian cancer cell lines</ArticleTitle>
                <JournalTitle>Am J Obstet Gynecol</JournalTitle>
                <VolumeID>191</VolumeID>
                <FirstPage>1164</FirstPage>
                <LastPage>1172</LastPage>
                <Occurrence Type="PID">
                  <Handle>15507937</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2cXovVKmtLg%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/j.ajog.2004.04.020</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Gunthert AR, Grundker C, Bongertz T, Schlott T, Nagy A, Schally AV. Internalization of cytotoxic luteinizing hormone-releasing hormone analog AN-152 induces multi drug resistance 1 (MDR-1) independent apoptosis in human endometrial and ovarian cancer cell lines. Am J Obstet Gynecol 2004:191:1164–1172.</BibUnstructured>
            </Citation>
            <Citation ID="CR84_2">
              <CitationNumber>84</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>WB</Initials>
                  <FamilyName>Peeling</FamilyName>
                </BibAuthorName>
                <Year>1989</Year>
                <ArticleTitle Language="En">Phase III studies to compare goserelin (Zoladex) with orchiectomy and with diethylstilbestrol in treatment of prostatic carcinoma</ArticleTitle>
                <JournalTitle>Urology</JournalTitle>
                <VolumeID>33</VolumeID>
                <IssueID>S</IssueID>
                <FirstPage>45</FirstPage>
                <LastPage>52</LastPage>
                <Occurrence Type="PID">
                  <Handle>2523611</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DyaL1M3isVSjtQ%3D%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/0090-4295(89)90106-4</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Peeling WB. Phase III studies to compare goserelin (Zoladex) with orchiectomy and with diethylstilbestrol in treatment of prostatic carcinoma. Urology 1989;33(S):45–52.</BibUnstructured>
            </Citation>
            <Citation ID="CR85_2">
              <CitationNumber>85</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>TW</Initials>
                  <FamilyName>Redding</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>AV</Initials>
                  <FamilyName>Schally</FamilyName>
                </BibAuthorName>
                <Year>1981</Year>
                <ArticleTitle Language="En">Inhibition of prostate tumour growth in two rat models by chronic administration of D-Trp<Superscript>6</Superscript>-LH-RH</ArticleTitle>
                <JournalTitle>Proc Natl Acad Sci USA</JournalTitle>
                <VolumeID>78</VolumeID>
                <FirstPage>6509</FirstPage>
                <LastPage>6512</LastPage>
                <Occurrence Type="PID">
                  <Handle>6458815</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaL3MXlvFyjt7s%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1073/pnas.78.10.6509</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Redding TW, Schally AV. Inhibition of prostate tumour growth in two rat models by chronic administration of D-Trp<Superscript>6</Superscript>-LH-RH. Proc Natl Acad Sci USA 1981;78:6509–6512.</BibUnstructured>
            </Citation>
            <Citation ID="CR86_2">
              <CitationNumber>86</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>G</Initials>
                  <FamilyName>Tolis</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>D</Initials>
                  <FamilyName>Ackman</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Stellos</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1982</Year>
                <ArticleTitle Language="En">Tumor growth inhibition in patients with prostatic carcinoma treated with luteinizing hormone-releasing agonists</ArticleTitle>
                <JournalTitle>Proc Natl Acad Sci USA</JournalTitle>
                <VolumeID>79</VolumeID>
                <FirstPage>1658</FirstPage>
                <LastPage>1662</LastPage>
                <Occurrence Type="PID">
                  <Handle>6461861</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DyaL387nsVKmuw%3D%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1073/pnas.79.5.1658</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Tolis G, Ackman D, Stellos A, et al. Tumor growth inhibition in patients with prostatic carcinoma treated with luteinizing hormone-releasing agonists. Proc Natl Acad Sci USA 1982;79:1658–1662.</BibUnstructured>
            </Citation>
            <Citation ID="CR87_2">
              <CitationNumber>87</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>PC</Initials>
                  <FamilyName>Sogani</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>WR</Initials>
                  <FamilyName>Fair</FamilyName>
                </BibAuthorName>
                <Year>1987</Year>
                <ArticleTitle Language="En">Treatment of advanced prostate cancer</ArticleTitle>
                <JournalTitle>Urol Clin North Am</JournalTitle>
                <VolumeID>14</VolumeID>
                <FirstPage>253</FirstPage>
                <LastPage>271</LastPage>
              </BibArticle>
              <BibUnstructured>Sogani PC, Fair WR. Treatment of advanced prostate cancer. Urol Clin North Am 1987;14:253–271.</BibUnstructured>
            </Citation>
            <Citation ID="CR88_2">
              <CitationNumber>88</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>ED</Initials>
                  <FamilyName>Crawford</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MA</Initials>
                  <FamilyName>Eisenberger</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DG</Initials>
                  <FamilyName>McLeod</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1989</Year>
                <ArticleTitle Language="En">A controlled trial of leuprolide with and without flutamide in prostatic carcinoma</ArticleTitle>
                <JournalTitle>N Engl J Med</JournalTitle>
                <VolumeID>321</VolumeID>
                <FirstPage>419</FirstPage>
                <LastPage>424</LastPage>
                <Occurrence Type="PID">
                  <Handle>2503724</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DyaL1MzksVWgtw%3D%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1056/NEJM198908173210702</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Crawford ED, Eisenberger MA, McLeod DG, et al. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 1989;321:419–424.</BibUnstructured>
            </Citation>
            <Citation ID="CR89_2">
              <CitationNumber>89</CitationNumber>
              <BibChapter>
                <BibAuthorName>
                  <Initials>D</Initials>
                  <FamilyName>Gonzalez-Barcena</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>AV</Initials>
                  <FamilyName>Schally</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>AM</Initials>
                  <FamilyName>Comaru-Schally</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Cortez-Morales</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Vadillo-Buenfil</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MA</Initials>
                  <FamilyName>Molina-Ayala</FamilyName>
                </BibAuthorName>
                <Year>1996</Year>
                <ChapterTitle Language="En">Treatment of patients with advanced prostate cancer with LH-RH antagonist Cetrorelix</ChapterTitle>
                <BibEditorName>
                  <Initials>M</Initials>
                  <FamilyName>Filicori</FamilyName>
                </BibEditorName>
                <BibEditorName>
                  <Initials>C</Initials>
                  <FamilyName>Flamigni</FamilyName>
                </BibEditorName>
                <Eds/>
                <BookTitle>Treatment with GnRH analogs: Controversies &amp; perspectives</BookTitle>
                <PublisherName>Parthenon</PublisherName>
                <PublisherLocation>London/New York</PublisherLocation>
                <FirstPage>139</FirstPage>
                <LastPage>144</LastPage>
              </BibChapter>
              <BibUnstructured>Gonzalez-Barcena D, Schally AV, Comaru-Schally AM, Cortez-Morales A, Vadillo-Buenfil M, Molina-Ayala MA. Treatment of patients with advanced prostate cancer with LH-RH antagonist Cetrorelix. In: Filicori M, Flamigni C, eds. Treatment with GnRH analogs: Controversies &amp; perspectives, London/New York: Parthenon, 1996;139–144.</BibUnstructured>
            </Citation>
            <Citation ID="CR90_2">
              <CitationNumber>90</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>D</Initials>
                  <FamilyName>Gonzalez-Barcena</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Vadillo-Buenfil</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Cortez-Morales</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1995</Year>
                <ArticleTitle Language="En">Luteinizing hormone-releasing hormone antagonist SB-75 (Cetrorelix) as primary single therapy in patients with advanced prostatic cancer and paraplegia due to metastatic invasion of spinal cord</ArticleTitle>
                <JournalTitle>Urology</JournalTitle>
                <VolumeID>45</VolumeID>
                <FirstPage>275</FirstPage>
                <LastPage>281</LastPage>
                <Occurrence Type="PID">
                  <Handle>7531902</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DyaK2M7lvFejsg%3D%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/0090-4295(95)80018-2</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Gonzalez-Barcena D, Vadillo-Buenfil M, Cortez-Morales A, et al. Luteinizing hormone-releasing hormone antagonist SB-75 (Cetrorelix) as primary single therapy in patients with advanced prostatic cancer and paraplegia due to metastatic invasion of spinal cord. Urology 1995;45:275–281.</BibUnstructured>
            </Citation>
            <Citation ID="CR91_2">
              <CitationNumber>91</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Trachtenberg</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2002</Year>
                <ArticleTitle Language="En">A phase 3, multicenter, open label, randomized study of abarelix versus leuprolide plus daily antiandrogen in men with prostate cancer</ArticleTitle>
                <JournalTitle>J Urol</JournalTitle>
                <VolumeID>167</VolumeID>
                <FirstPage>1670</FirstPage>
                <LastPage>1674</LastPage>
                <Occurrence Type="PID">
                  <Handle>11912385</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD38XislOmsb0%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1097/00005392-200204000-00021</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Trachtenberg J, et al. A phase 3, multicenter, open label, randomized study of abarelix versus leuprolide plus daily antiandrogen in men with prostate cancer. J Urol 2002;167:1670–1674.</BibUnstructured>
            </Citation>
            <Citation ID="CR92_2">
              <CitationNumber>92</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>MB</Initials>
                  <FamilyName>Garnick</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Campion</FamilyName>
                </BibAuthorName>
                <Year>2000</Year>
                <ArticleTitle Language="En">Abarelix Depot, a GnRH antagonist, v LHRH superagonists in prostate cancer: Differential effects on follicle-stimulating hormone. Abarelix study group</ArticleTitle>
                <JournalTitle>Mol Urol</JournalTitle>
                <VolumeID>4</VolumeID>
                <FirstPage>275</FirstPage>
                <LastPage>277</LastPage>
                <Occurrence Type="PID">
                  <Handle>11062384</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3cXnvV2lu7k%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Garnick MB, Campion M. Abarelix Depot, a GnRH antagonist, v LHRH superagonists in prostate cancer: differential effects on follicle-stimulating hormone. Abarelix study group. Mol Urol 2000;4:275–277.</BibUnstructured>
            </Citation>
            <Citation ID="CR93_2">
              <CitationNumber>93</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>TM</Initials>
                  <FamilyName>Beer</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>C</Initials>
                  <FamilyName>Ryan</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>G</Initials>
                  <FamilyName>Bhat</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Garnick</FamilyName>
                </BibAuthorName>
                <InstitutionalAuthorName>Abarelix Study Group</InstitutionalAuthorName>
                <Year>2006</Year>
                <ArticleTitle Language="En">Dose-escalated abarelix in androgen-independent prostate cancer: A phase I study</ArticleTitle>
                <JournalTitle>Anti-Cancer Drugs</JournalTitle>
                <VolumeID>17</VolumeID>
                <FirstPage>1075</FirstPage>
                <LastPage>1079</LastPage>
                <Occurrence Type="PID">
                  <Handle>17001181</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD28XpvFersbY%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1097/01.cad.0000231476.84782.55</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Beer TM, Ryan C, Bhat G, Garnick M, Abarelix Study Group. Dose-escalated abarelix in androgen-independent prostate cancer: A phase I study. Anti-Cancer Drugs 2006;17:1075–1079.</BibUnstructured>
            </Citation>
            <Citation ID="CR94_2">
              <CitationNumber>94</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>AV</Initials>
                  <FamilyName>Schally</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JL</Initials>
                  <FamilyName>Varga</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JB</Initials>
                  <FamilyName>Engel</FamilyName>
                </BibAuthorName>
                <Year>2008</Year>
                <ArticleTitle Language="En">Drug insight: Antagonistic growth hormone-releasing hormone: An emerging new therapy for cancer</ArticleTitle>
                <JournalTitle>Nat Clin Pract Endocrinol Metab</JournalTitle>
                <VolumeID>4</VolumeID>
                <FirstPage>33</FirstPage>
                <LastPage>43</LastPage>
                <Occurrence Type="PID">
                  <Handle>18084344</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2sXhsVegtbfE</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1038/ncpendmet0677</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Schally AV, Varga JL, Engel JB. Drug Insight: Antagonistic growth hormone-releasing hormone: An emerging new therapy for cancer. Nat Clin Pract Endocrinol Metab 2008;4:33–43.</BibUnstructured>
            </Citation>
            <Citation ID="CR95_2">
              <CitationNumber>95</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Stangelberger</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>AV</Initials>
                  <FamilyName>Schally</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Zarandi</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2007</Year>
                <ArticleTitle Language="En">The combination of antagonists of LHRH with antagonists of GHRH improves inhibition of androgen sensitive MDA-Pca-2b and LuCaP-35 prostate cancers</ArticleTitle>
                <JournalTitle>Prostate</JournalTitle>
                <VolumeID>67</VolumeID>
                <FirstPage>1339</FirstPage>
                <LastPage>1353</LastPage>
                <Occurrence Type="PID">
                  <Handle>17624923</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2sXhtFGgtLbK</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1002/pros.20605</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Stangelberger A, Schally AV, Zarandi M, et al. The combination of antagonists of LHRH with antagonists of GHRH improves inhibition of androgen sensitive MDA-Pca-2b and LuCaP-35 prostate cancers. Prostate 2007;67:1339–1353.</BibUnstructured>
            </Citation>
            <Citation ID="CR96_2">
              <CitationNumber>96</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Letsch</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>AV</Initials>
                  <FamilyName>Schally</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>K</Initials>
                  <FamilyName>Szepeshazi</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>G</Initials>
                  <FamilyName>Halmos</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Nagy</FamilyName>
                </BibAuthorName>
                <Year>2003</Year>
                <ArticleTitle Language="En">Preclinical evaluation of targeted cytotoxic luteinizing hormone-releasing hormone analogue AN-152 in androgen-sensitive and insensitive prostate cancers</ArticleTitle>
                <JournalTitle>Clin Cancer Res</JournalTitle>
                <VolumeID>9</VolumeID>
                <FirstPage>4505</FirstPage>
                <LastPage>4513</LastPage>
                <Occurrence Type="PID">
                  <Handle>14555524</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3sXotVShtrs%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Letsch M, Schally AV, Szepeshazi K, Halmos G, Nagy A. Preclinical evaluation of targeted cytotoxic luteinizing hormone-releasing hormone analogue AN-152 in androgen-sensitive and insensitive prostate cancers. Clin Cancer Res 2003;9:4505–4513.</BibUnstructured>
            </Citation>
            <Citation ID="CR97_2">
              <CitationNumber>97</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Plonowski</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>AV</Initials>
                  <FamilyName>Schally</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Nagy</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2002</Year>
                <ArticleTitle Language="En">Inhibition of in vivo proliferation of MDA-Pca-2b human prostate cancer by targeted cytotoxic analog of luteinizing hormone-releasing hormone AN-207</ArticleTitle>
                <JournalTitle>Cancer Lett</JournalTitle>
                <VolumeID>176</VolumeID>
                <FirstPage>57</FirstPage>
                <LastPage>63</LastPage>
                <Occurrence Type="PID">
                  <Handle>11790454</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD38XktFarsA%3D%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/S0304-3835(01)00734-0</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Plonowski A, Schally AV, Nagy A, et al. Inhibition of in vivo proliferation of MDA-Pca-2b human prostate cancer by targeted cytotoxic analog of luteinizing hormone-releasing hormone AN-207. Cancer Lett 2002;176:57–63.</BibUnstructured>
            </Citation>
            <Citation ID="CR98_2">
              <CitationNumber>98</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Kovács</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>AV</Initials>
                  <FamilyName>Schally</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Nagy</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Koppán</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>K</Initials>
                  <FamilyName>Groot</FamilyName>
                </BibAuthorName>
                <Year>1997</Year>
                <ArticleTitle Language="En">Recovery of pituitary function after treatment with a targeted cytotoxic analog of luteinizing hormone-releasing hormone</ArticleTitle>
                <JournalTitle>Proc Natl Acad Sci USA</JournalTitle>
                <VolumeID>94</VolumeID>
                <FirstPage>1420</FirstPage>
                <LastPage>1425</LastPage>
                <Occurrence Type="PID">
                  <Handle>9037068</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1073/pnas.94.4.1420</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Kovács M, Schally AV, Nagy A, Koppán M, Groot K. Recovery of pituitary function after treatment with a targeted cytotoxic analog of luteinizing hormone-releasing hormone. Proc Natl Acad Sci USA 1997;94:1420–1425.</BibUnstructured>
            </Citation>
            <Citation ID="CR99_2">
              <CitationNumber>99</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Kovács</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>AV</Initials>
                  <FamilyName>Schally</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>B</Initials>
                  <FamilyName>Csernus</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>R</Initials>
                  <FamilyName>Busto</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>Z</Initials>
                  <FamilyName>Rékási</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Nagy</FamilyName>
                </BibAuthorName>
                <Year>2002</Year>
                <ArticleTitle Language="En">Targeted cytotoxic analogue of luteinizing hormone-releasing hormone (LH-RH) only transiently decreases the gene expression of pituitary receptors for LH-RH</ArticleTitle>
                <JournalTitle>J Neuroendocrinol</JournalTitle>
                <VolumeID>14</VolumeID>
                <FirstPage>5</FirstPage>
                <LastPage>13</LastPage>
                <Occurrence Type="PID">
                  <Handle>11903807</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1046/j.0007-1331.2001.00728.x</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Kovács M, Schally AV, Csernus B, Busto R, Rékási Z, Nagy A. Targeted cytotoxic analogue of luteinizing hormone-releasing hormone (LH-RH) only transiently decreases the gene expression of pituitary receptors for LH-RH. J Neuroendocrinol 2002;14:5–13.</BibUnstructured>
            </Citation>
            <Citation ID="CR100_2">
              <CitationNumber>100</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>G</Initials>
                  <FamilyName>Emons</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Kauffmann</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>AR</Initials>
                  <FamilyName>Gunthert</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2007</Year>
                <ArticleTitle Language="En">Phase I study of Zen-008 (AN-152), a targeted cytotoxic LHRH analog in female patients with cancers expressing LHRH receptors</ArticleTitle>
                <JournalTitle>J Clin Oncol</JournalTitle>
                <VolumeID>25</VolumeID>
                <IssueID>18S</IssueID>
                <FirstPage>3571</FirstPage>
                <BibComments>ASCO Annual Meeting Proceedings</BibComments>
              </BibArticle>
              <BibUnstructured>Emons G, Kauffmann M, Gunthert AR, et al. Phase I study of Zen-008 (AN-152), a targeted cytotoxic LHRH analog in female patients with cancers expressing LHRH receptors. J Clin Oncol, ASCO Annual Meeting Proceedings 2007;25(18S):3571.</BibUnstructured>
            </Citation>
          </Bibliography>
        </ChapterBackmatter>
      </Chapter>
    </Part>
  </Book>
</Publisher>
